<!DOCTYPE html>
<html lang="en-US" data-bt-theme="Industrial 1.3.1">
<head>

<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="robots" content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1">
<script type="06cd7e663a0e46d4271fe72d-text/javascript">if(navigator.userAgent.match(/MSIE|Internet Explorer/i)||navigator.userAgent.match(/Trident\/7\..*?rv:11/i)){var href=document.location.href;if(!href.match(/[?&]nowprocket/)){if(href.indexOf("?")==-1){if(href.indexOf("#")==-1){document.location.href=href+"?nowprocket=1"}else{document.location.href=href.replace("#","?nowprocket=1#")}}else{if(href.indexOf("#")==-1){document.location.href=href+"&nowprocket=1"}else{document.location.href=href.replace("#","&nowprocket=1#")}}}}</script><script type="06cd7e663a0e46d4271fe72d-text/javascript">class RocketLazyLoadScripts{constructor(e){this.triggerEvents=e,this.eventOptions={passive:!0},this.userEventListener=this.triggerListener.bind(this),this.delayedScripts={normal:[],async:[],defer:[]},this.allJQueries=[]}_addUserInteractionListener(e){this.triggerEvents.forEach((t=>window.addEventListener(t,e.userEventListener,e.eventOptions)))}_removeUserInteractionListener(e){this.triggerEvents.forEach((t=>window.removeEventListener(t,e.userEventListener,e.eventOptions)))}triggerListener(){this._removeUserInteractionListener(this),"loading"===document.readyState?document.addEventListener("DOMContentLoaded",this._loadEverythingNow.bind(this)):this._loadEverythingNow()}async _loadEverythingNow(){this._delayEventListeners(),this._delayJQueryReady(this),this._handleDocumentWrite(),this._registerAllDelayedScripts(),this._preloadAllScripts(),await this._loadScriptsFromList(this.delayedScripts.normal),await this._loadScriptsFromList(this.delayedScripts.defer),await this._loadScriptsFromList(this.delayedScripts.async),await this._triggerDOMContentLoaded(),await this._triggerWindowLoad(),window.dispatchEvent(new Event("rocket-allScriptsLoaded"))}_registerAllDelayedScripts(){document.querySelectorAll("script[type=rocketlazyloadscript]").forEach((e=>{e.hasAttribute("src")?e.hasAttribute("async")&&!1!==e.async?this.delayedScripts.async.push(e):e.hasAttribute("defer")&&!1!==e.defer||"module"===e.getAttribute("data-rocket-type")?this.delayedScripts.defer.push(e):this.delayedScripts.normal.push(e):this.delayedScripts.normal.push(e)}))}async _transformScript(e){return await this._requestAnimFrame(),new Promise((t=>{const n=document.createElement("script");let i;[...e.attributes].forEach((e=>{let t=e.nodeName;"type"!==t&&("data-rocket-type"===t&&(t="type",i=e.nodeValue),n.setAttribute(t,e.nodeValue))})),e.hasAttribute("src")&&this._isValidScriptType(i)?(n.addEventListener("load",t),n.addEventListener("error",t)):(n.text=e.text,t()),e.parentNode.replaceChild(n,e)}))}_isValidScriptType(e){return!e||""===e||"string"==typeof e&&["text/javascript","text/x-javascript","text/ecmascript","text/jscript","application/javascript","application/x-javascript","application/ecmascript","application/jscript","module"].includes(e.toLowerCase())}async _loadScriptsFromList(e){const t=e.shift();return t?(await this._transformScript(t),this._loadScriptsFromList(e)):Promise.resolve()}_preloadAllScripts(){var e=document.createDocumentFragment();[...this.delayedScripts.normal,...this.delayedScripts.defer,...this.delayedScripts.async].forEach((t=>{const n=t.getAttribute("src");if(n){const t=document.createElement("link");t.href=n,t.rel="preload",t.as="script",e.appendChild(t)}})),document.head.appendChild(e)}_delayEventListeners(){let e={};function t(t,n){!function(t){function n(n){return e[t].eventsToRewrite.indexOf(n)>=0?"rocket-"+n:n}e[t]||(e[t]={originalFunctions:{add:t.addEventListener,remove:t.removeEventListener},eventsToRewrite:[]},t.addEventListener=function(){arguments[0]=n(arguments[0]),e[t].originalFunctions.add.apply(t,arguments)},t.removeEventListener=function(){arguments[0]=n(arguments[0]),e[t].originalFunctions.remove.apply(t,arguments)})}(t),e[t].eventsToRewrite.push(n)}function n(e,t){let n=e[t];Object.defineProperty(e,t,{get:()=>n||function(){},set(i){e["rocket"+t]=n=i}})}t(document,"DOMContentLoaded"),t(window,"DOMContentLoaded"),t(window,"load"),t(window,"pageshow"),t(document,"readystatechange"),n(document,"onreadystatechange"),n(window,"onload"),n(window,"onpageshow")}_delayJQueryReady(e){let t=window.jQuery;Object.defineProperty(window,"jQuery",{get:()=>t,set(n){if(n&&n.fn&&!e.allJQueries.includes(n)){n.fn.ready=n.fn.init.prototype.ready=function(t){e.domReadyFired?t.bind(document)(n):document.addEventListener("rocket-DOMContentLoaded",(()=>t.bind(document)(n)))};const t=n.fn.on;n.fn.on=n.fn.init.prototype.on=function(){if(this[0]===window){function e(e){return e.split(" ").map((e=>"load"===e||0===e.indexOf("load.")?"rocket-jquery-load":e)).join(" ")}"string"==typeof arguments[0]||arguments[0]instanceof String?arguments[0]=e(arguments[0]):"object"==typeof arguments[0]&&Object.keys(arguments[0]).forEach((t=>{delete Object.assign(arguments[0],{[e(t)]:arguments[0][t]})[t]}))}return t.apply(this,arguments),this},e.allJQueries.push(n)}t=n}})}async _triggerDOMContentLoaded(){this.domReadyFired=!0,await this._requestAnimFrame(),document.dispatchEvent(new Event("rocket-DOMContentLoaded")),await this._requestAnimFrame(),window.dispatchEvent(new Event("rocket-DOMContentLoaded")),await this._requestAnimFrame(),document.dispatchEvent(new Event("rocket-readystatechange")),await this._requestAnimFrame(),document.rocketonreadystatechange&&document.rocketonreadystatechange()}async _triggerWindowLoad(){await this._requestAnimFrame(),window.dispatchEvent(new Event("rocket-load")),await this._requestAnimFrame(),window.rocketonload&&window.rocketonload(),await this._requestAnimFrame(),this.allJQueries.forEach((e=>e(window).trigger("rocket-jquery-load"))),window.dispatchEvent(new Event("rocket-pageshow")),await this._requestAnimFrame(),window.rocketonpageshow&&window.rocketonpageshow()}_handleDocumentWrite(){const e=new Map;document.write=document.writeln=function(t){const n=document.currentScript;n||console.error("WPRocket unable to document.write this: "+t);const i=document.createRange(),r=n.parentElement;let a=e.get(n);void 0===a&&(a=n.nextSibling,e.set(n,a));const o=document.createDocumentFragment();i.setStart(o,0),o.appendChild(i.createContextualFragment(t)),r.insertBefore(o,a)}}async _requestAnimFrame(){return new Promise((e=>requestAnimationFrame(e)))}static run(){const e=new RocketLazyLoadScripts(["keydown","mousemove","touchmove","touchstart","touchend","wheel"]);e._addUserInteractionListener(e)}}RocketLazyLoadScripts.run();
</script>
<title>Active pharmaceutical ingredients - Ikigai&reg; Corporation</title>
<link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CMontserrat%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CMontserrat%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CRoboto%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CMontserrat%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CRoboto%3A100%2C100italic%2C200%2C200italic%2C300%2C300italic%2C400%2C400italic%2C500%2C500italic%2C600%2C600italic%2C700%2C700italic%2C800%2C800italic%2C900%2C900italic%7CRoboto%20Slab%3A100%2C100italic%2C200%2C200italic%2C300%2C300italic%2C400%2C400italic%2C500%2C500italic%2C600%2C600italic%2C700%2C700italic%2C800%2C800italic%2C900%2C900italic&#038;subset=latin%2Clatin-ext&#038;display=swap">
<link rel="stylesheet" href="./../../../../wp-content/cache/min/1/94ef57cb2a7e04898d8df31f764bfef2.css" media="all" data-minify="1">
<meta name="description" content="API (Active Pharmaceutical Ingredient) determines the active component which is included in the medicine. CATEGORY :ALLAPI. ANTIBIOTICSAPI. BOLDENONE SERIESAPI. CANRENONE DERIVATIVESAPI. CORTICAL STEROIDAPI. DHEA &amp; DERIVATIVESAPI. ESTROGENAPI. NANDROLONE SERIESAPI. OTHERSAPI. PROGESTERONE &amp; INTERMEDIATEAPI. STARTING MATERIALAPI. TESTOSTERONE SERIES">
<link rel="canonical" href="./index.html">
<meta property="og:locale" content="en_US">
<meta property="og:type" content="article">
<meta property="og:title" content="Active pharmaceutical ingredients - Ikigai&reg; Corporation">
<meta property="og:description" content="API (Active Pharmaceutical Ingredient) determines the active component which is included in the medicine. CATEGORY :ALLAPI. ANTIBIOTICSAPI. BOLDENONE SERIESAPI. CANRENONE DERIVATIVESAPI. CORTICAL STEROIDAPI. DHEA &amp; DERIVATIVESAPI. ESTROGENAPI. NANDROLONE SERIESAPI. OTHERSAPI. PROGESTERONE &amp; INTERMEDIATEAPI. STARTING MATERIALAPI. TESTOSTERONE SERIES">
<meta property="og:url" content="./active-pharmaceutical-ingredients/">
<meta property="og:site_name" content="Ikigai&reg; Corporation">
<meta property="article:modified_time" content="2021-01-28T12:32:49+00:00">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:label1" content="Est. reading time">
<meta name="twitter:data1" content="1 minute">
<script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"WebSite","@id":"./#website","url":"./","name":"Ikigai&reg; Corporation","description":"Leading suppliers of API (active pharmaceutical ingredients)","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"./?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"WebPage","@id":"./active-pharmaceutical-ingredients/#webpage","url":"./active-pharmaceutical-ingredients/","name":"Active pharmaceutical ingredients - Ikigai&reg; Corporation","isPartOf":{"@id":"./#website"},"datePublished":"2020-01-30T19:55:43+00:00","dateModified":"2021-01-28T12:32:49+00:00","description":"API (Active Pharmaceutical Ingredient) determines the active component which is included in the medicine. CATEGORY :ALLAPI. ANTIBIOTICSAPI. BOLDENONE SERIESAPI. CANRENONE DERIVATIVESAPI. CORTICAL STEROIDAPI. DHEA & DERIVATIVESAPI. ESTROGENAPI. NANDROLONE SERIESAPI. OTHERSAPI. PROGESTERONE & INTERMEDIATEAPI. STARTING MATERIALAPI. TESTOSTERONE SERIES","breadcrumb":{"@id":"./active-pharmaceutical-ingredients/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["./active-pharmaceutical-ingredients/"]}]},{"@type":"BreadcrumbList","@id":"./active-pharmaceutical-ingredients/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"./"},{"@type":"ListItem","position":2,"name":"Active pharmaceutical ingredients"}]}]}</script>

<link rel="dns-prefetch" href="https://use.fontawesome.com">
<link rel="dns-prefetch" href="https://fonts.googleapis.com">
<link href="https://fonts.gstatic.com" crossorigin rel="preconnect">
<style type="text/css">img.wp-smiley,
img.emoji {
	display: inline !important;
	border: none !important;
	box-shadow: none !important;
	height: 1em !important;
	width: 1em !important;
	margin: 0 .07em !important;
	vertical-align: -0.1em !important;
	background: none !important;
	padding: 0 !important;
}</style>

<style id="industrial-style-inline-css" type="text/css">select, input{font-family: Roboto;} input:not([type='checkbox']):not([type='radio']), textarea, select{ font-family: "Montserrat";} input:not([type='checkbox']):not([type='radio']):not([type='submit']):focus, textarea:focus{-webkit-box-shadow: 0 0 4px 0 #58a0d3; box-shadow: 0 0 4px 0 #58a0d3;} html a:hover, .btLightSkin a:hover, .btDarkSkin .btLightSkin a:hover, .btLightSkin .btDarkSkin .btLightSkin a:hover, .btDarkSkin a:hover, .btLightSkin .btDarkSkin a:hover, .btDarkSkin.btLightSkin .btDarkSkin a:hover{ color: #58a0d3;} .btLightSkin .btText a, .btDarkSkin .btLightSkin .btText a, .btLightSkin .btDarkSkin .btLightSkin .btText a, .btDarkSkin .btText a, .btLightSkin .btDarkSkin .btText a, .btDarkSkin.btLightSkin .btDarkSkin .btText a{color: #58a0d3;} body{font-family: "Roboto",Arial,sans-serif;} .btContentHolder cite{ font-family: Montserrat;} h1, h2, h3, h4, h5, h6{font-family: "Montserrat";} .btContentHolder table thead th{ background-color: #58a0d3; font-family: Montserrat;} .btAccentColorBackground{background-color: #58a0d3 !important;} .btAccentColorBackground .headline b.animate.animated{color: #1a86d3;} .btAccentColorBackground .btDash.bottomDash .dash:after{border-color: #1a86d3;} .btAccentDarkColorBackground{background-color: #2e7ab0 !important;} .btAccentDarkColorBackground .headline b.animate.animated{color: #1a86d3;} .btAccentVeryDarkColorBackground{background-color: #19425f !important;} .btAccentLightColorBackground{background-color: rgba(88,160,211,0.7) !important;} .btAlternateColorBackground{background-color: #1a86d3 !important;} .btAlternateDarkColorBackground{background-color: #125b8f !important;} .btAlternateVeryDarkColorBackground{background-color: #0c3e61 !important;} .btAlternateLightColorBackground{background-color: rgba(26,134,211,0.6) !important;} .btAccentDarkHeader .btPreloader .animation > div:first-child, .btLightAccentHeader .btPreloader .animation > div:first-child{ background-color: #2e7ab0;} .btPreloader .animation .preloaderLogo{height: 100px;} .mainHeader{ font-family: "Montserrat";} .btMenuVertical.btAccentDarkHeader .mainHeader, .btMenuVertical.btLightAccentHeader .mainHeader{background-color: #58a0d3;} .btMenuVertical.btLightAlternateHeader .mainHeader{background-color: #1a86d3;} .menuPort{font-family: "Montserrat";} .menuPort nav ul li a:hover{color: #58a0d3 !important;} .menuPort nav > ul > li > a{line-height: 100px;} .btTextLogo{ line-height: 100px;} .btLogoArea .logo img{height: 100px;} .btHorizontalMenuTrigger{ line-height: 100px;} .btMenuHorizontal .menuPort nav > ul > li.current-menu-ancestor > a:after, .btMenuHorizontal .menuPort nav > ul > li.current-menu-item > a:after{ background-color: #58a0d3;} .btAccentDarkHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-ancestor > a:after, .btAccentDarkHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-item > a:after, .btAccentLightHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-ancestor > a:after, .btAccentLightHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-item > a:after{background-color: #1a86d3;} .btMenuHorizontal .menuPort nav > ul > li > ul li.current-menu-ancestor > a, .btMenuHorizontal .menuPort nav > ul > li > ul li.current-menu-item > a{color: #58a0d3 !important;} body.btMenuHorizontal .subToggler{ line-height: 100px;} .btMenuHorizontal .topBarInMenu{ height: 100px;} .btLightSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btLightSkin.btAccentLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .btBelowLogoArea, .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .topBar, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .btBelowLogoArea, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .topBar{background-color: #58a0d3;} .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .btBelowLogoArea:before, .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .topBar:before, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .btBelowLogoArea:before, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .topBar:before{ background-color: #58a0d3;} .btAccentLightHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .btBelowLogoArea, .btAccentLightHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .topBar{background-color: #58a0d3;} .btLightSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btLightSkin.btLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btLightSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .menuPort > nav > ul > li > a:hover, .btDarkSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btAccentDarkHeader.btMenuHorizontal:not(.btBelowMenu) .mainHeader, .btAccentDarkHeader.btMenuHorizontal.btStickyHeaderActive .mainHeader{background-color: #58a0d3;} .btAccentDarkHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .port .btLogoArea{background-color: #58a0d3;} .btLightSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btLightAccentHeader.btMenuHorizontal:not(.btBelowMenu) .mainHeader, .btLightAccentHeader.btMenuHorizontal.btStickyHeaderActive .mainHeader{background-color: #58a0d3;} .btLightAccentHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .port .btLogoArea{background-color: #58a0d3;} .btLightSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover{color: #58a0d3 !important;} .btLightAlternateHeader.btMenuHorizontal:not(.btBelowMenu) .mainHeader, .btLightAlternateHeader.btMenuHorizontal.btStickyHeaderActive .mainHeader{background-color: #1a86d3;} .btLightAlternateHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .port .btLogoArea{background-color: #1a86d3;} .btAccentDarkHeader.btMenuVertical > .menuPort .logo, .btLightAccentHeader.btMenuVertical > .menuPort .logo{background-color: #58a0d3;} .btLightAlternateHeader.btMenuVertical > .menuPort .logo{background-color: #1a86d3;} .btMenuVertical > .menuPort .btCloseVertical:before:hover{color: #58a0d3;} @media (min-width: 1200px){.btMenuVerticalOn .btVerticalMenuTrigger .btIco a:before{color: #58a0d3 !important;} }.btMenuHorizontal .topBarInLogoArea{ height: 100px;} .btMenuHorizontal .topBarInLogoArea .topBarInLogoAreaCell{border: 0 solid #58a0d3;} .btSearchInner.btFromTopBox{ background: #58a0d3;} .btSearchInner.btFromTopBox form button:hover:before{color: #58a0d3;} .btDarkSkin .btSiteFooter .port:before, .btLightSkin .btDarkSkin .btSiteFooter .port:before, .btDarkSkin.btLightSkin .btDarkSkin .btSiteFooter .port:before{background-color: #58a0d3;} .btMediaBox.btQuote, .btMediaBox.btLink{ background-color: #58a0d3;} .btArticleListItem .headline a:hover{color: #58a0d3;} .btCommentsBox .vcard .posted{ font-family: "Montserrat";} .btCommentsBox .commentTxt p.edit-link, .btCommentsBox .commentTxt p.reply{ font-family: "Montserrat";} .comment-respond .btnOutline button[type="submit"]{font-family: "Montserrat";} a#cancel-comment-reply-link:hover{color: #58a0d3;} .post-password-form input[type="submit"]{ background: #58a0d3; font-family: "Montserrat";} .btPagination{font-family: "Montserrat";} .btPagination .paging a:hover:after{border-color: #58a0d3;} span.btHighlight{ background-color: #58a0d3;} .btArticleCategories a:not(:first-child):before{ background-color: #58a0d3;} .btArticleMeta{font-family: "Montserrat";} body:not(.btNoDashInSidebar) .btBox > h4:after, body:not(.btNoDashInSidebar) .btCustomMenu > h4:after, body:not(.btNoDashInSidebar) .btTopBox > h4:after{ border-bottom: 3px solid #58a0d3;} .btBox ul li.current-menu-item > a, .btCustomMenu ul li.current-menu-item > a, .btTopBox ul li.current-menu-item > a{color: #58a0d3;} .btBox .ppTxt .header .headline a a:hover, .btCustomMenu .ppTxt .header .headline a a:hover, .btTopBox .ppTxt .header .headline a a:hover{color: #58a0d3;} .btBox p.posted, .btBox .quantity, .btCustomMenu p.posted, .btCustomMenu .quantity, .btTopBox p.posted, .btTopBox .quantity{ font-family: Montserrat;} .widget_calendar table caption{background: #58a0d3; font-family: "Montserrat";} .widget_rss li a.rsswidget{font-family: "Montserrat";} .fancy-select .trigger.open{color: #58a0d3;} .fancy-select ul.options li:hover{color: #58a0d3;} .widget_shopping_cart .total{ font-family: Montserrat;} .widget_shopping_cart .widget_shopping_cart_content .mini_cart_item .ppRemove a.remove{ background-color: #58a0d3;} .widget_shopping_cart .widget_shopping_cart_content .mini_cart_item .ppRemove a.remove:hover{background-color: #1a86d3;} .menuPort .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetIcon span.cart-contents, .topTools .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetIcon span.cart-contents, .topBarInLogoArea .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetIcon span.cart-contents{ background-color: #1a86d3; font: normal 10px/1 Montserrat;} .btMenuVertical .menuPort .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetInnerContent .verticalMenuCartToggler, .btMenuVertical .topTools .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetInnerContent .verticalMenuCartToggler, .btMenuVertical .topBarInLogoArea .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetInnerContent .verticalMenuCartToggler{ background-color: #58a0d3;} .widget_recent_reviews{font-family: Montserrat;} .widget_price_filter .price_slider_wrapper .ui-slider .ui-slider-handle{ background-color: #58a0d3;} .btBox .tagcloud a, .btTags ul a{ background: #58a0d3; font-family: "Montserrat";} .btSidebar .btIconWidget:hover .btIconWidgetText, footer .btIconWidget:hover .btIconWidgetText{color: #58a0d3;} .btTopBox.widget_bt_text_image .widget_sp_image-description{ font-family: 'Roboto',arial,sans-serif;} .btMenuHorizontal .topTools .btIconWidget:hover, .btMenuHorizontal .topBarInMenu .btIconWidget:hover{color: #58a0d3;} .btMenuHorizontal .topTools .btAccentIconWidget, .btMenuHorizontal .topBarInMenu .btAccentIconWidget{background-color: #58a0d3;} .btTopToolsInMenuArea.btMenuHorizontal .topTools .btAccentIconWidget, .btTopToolsInMenuArea.btMenuHorizontal .topBarInMenu .btAccentIconWidget{background-color: #1a86d3;} .btTopToolsInMenuArea.btMenuHorizontal .topTools .btAccentIconWidget:hover, .btTopToolsInMenuArea.btMenuHorizontal .topBarInMenu .btAccentIconWidget:hover{color: #58a0d3;} .btAccentLightHeader.btMenuHorizontal .topTools .btAccentIconWidget, .btLightAccentHeader.btMenuHorizontal .topTools .btAccentIconWidget, .btAccentLightHeader.btMenuHorizontal .topBarInMenu .btAccentIconWidget, .btLightAccentHeader.btMenuHorizontal .topBarInMenu .btAccentIconWidget{background-color: #1a86d3;} .btMenuHorizontal .topTools .btAccentIconWidget:hover, .btMenuHorizontal .topBarInMenu .btAccentIconWidget:hover{color: #1a86d3;} .btTopToolsInMenuArea.btLightAccentHeader.btMenuHorizontal .topTools .btAccentIconWidget:hover, .btTopToolsInMenuArea.btLightAccentHeader.btMenuHorizontal .topBarInMenu .btAccentIconWidget:hover{background-color: #58a0d3;} .btLightSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btLightSkin.btAccentLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before, .btLightSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btLightSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before{color: #1a86d3;} .btLightSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType .btIcoHolder:hover:before, .btDarkSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before{color: #1a86d3;} .btLightSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before, .btDarkSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before{color: #58a0d3;} .btLightSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before, .btDarkSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before{color: #58a0d3;} .btSpecialHeaderIcon .btIco .btIcoHolder:before, .btSpecialHeaderIcon .btIconWidgetTitle, .btSpecialHeaderIcon .btIconWidgetText{color: #58a0d3 !important;} .btLightSkin .btBox .btSearch button:hover, .btDarkSkin .btLightSkin .btBox .btSearch button:hover, .btLightSkin .btDarkSkin .btLightSkin .btBox .btSearch button:hover, .btDarkSkin .btBox .btSearch button:hover, .btLightSkin .btDarkSkin .btBox .btSearch button:hover, .btDarkSkin.btLightSkin .btDarkSkin .btBox .btSearch button:hover, .btLightSkin form.woocommerce-product-search button:hover, .btDarkSkin .btLightSkin form.woocommerce-product-search button:hover, .btLightSkin .btDarkSkin .btLightSkin form.woocommerce-product-search button:hover, .btDarkSkin form.woocommerce-product-search button:hover, .btLightSkin .btDarkSkin form.woocommerce-product-search button:hover, .btDarkSkin.btLightSkin .btDarkSkin form.woocommerce-product-search button:hover{background: #58a0d3 !important; border-color: #58a0d3 !important;} .topTools .widget_search button, .topBarInMenu .widget_search button{ background: #58a0d3;} .topTools .widget_search button:before, .topBarInMenu .widget_search button:before{ color: #58a0d3;} .topTools .widget_search button:hover, .topBarInMenu .widget_search button:hover{background: #2e7ab0;} .btIcoFilledType.btIcoAccentColor.btIconHexagonShape.btIco .btIcoHolder .hex{fill: #58a0d3;} .btIcoFilledType.btIcoAlternateColor.btIconHexagonShape.btIco .btIcoHolder .hex{fill: #1a86d3;} .btIcoOutlineType.btIcoAccentColor.btIconHexagonShape.btIco .btIcoHolder .hex{ stroke: #58a0d3;} .btIcoOutlineType.btIcoAlternateColor.btIconHexagonShape.btIco .btIcoHolder .hex{ stroke: #1a86d3;} .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex{fill: #58a0d3; stroke: #58a0d3;} .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex{fill: #1a86d3; stroke: #1a86d3;} .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex{ stroke: #1a86d3;} .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex{ stroke: #58a0d3;} .btIconHexagonShape .btIco.btIcoFilledType .btIcoHolder svg .hex{ fill: #58a0d3;} .btIconHexagonShape .btIco.btIcoFilledType:hover .btIcoHolder svg .hex{stroke: #58a0d3;} .btIconHexagonShape .btIco.btIcoOutlineType .btIcoHolder svg .hex{stroke: #58a0d3;} .btIconHexagonShape .btIco.btIcoOutlineType:hover .btIcoHolder svg .hex{stroke: #58a0d3; fill: #58a0d3;} .btIco.btIcoFilledType.btIcoAccentColor .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAccentColor:hover .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1em #58a0d3 inset; box-shadow: 0 0 0 1em #58a0d3 inset;} .btIco.btIcoFilledType.btIcoAccentColor:hover .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAccentColor .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset; box-shadow: 0 0 0 1px #58a0d3 inset; color: #58a0d3;} .btIco.btIcoFilledType.btIcoAlternateColor .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAlternateColor:hover .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1em #1a86d3 inset; box-shadow: 0 0 0 1em #1a86d3 inset;} .btIco.btIcoFilledType.btIcoAlternateColor:hover .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAlternateColor .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1px #1a86d3 inset; box-shadow: 0 0 0 1px #1a86d3 inset; color: #1a86d3;} .btLightSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btLightSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btLightSkin .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btDarkSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btDarkSkin.btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before{color: #58a0d3;} .btLightSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btDarkSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btDarkSkin.btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before{color: #1a86d3;} .btIcoAccentColor span{color: #58a0d3;} .btIcoAlternateColor span{color: #1a86d3;} .btIcoDefaultColor:hover span{color: #58a0d3;} .btBtn{ font-family: "Montserrat";} .btnFilledStyle.btnAccentColor, .btnOutlineStyle.btnAccentColor:hover{background-color: #58a0d3; border: 2px solid #58a0d3;} .btnOutlineStyle.btnAccentColor, .btnFilledStyle.btnAccentColor:hover{ border: 2px solid #58a0d3; color: #58a0d3;} .btnOutlineStyle.btnAccentColor span, .btnFilledStyle.btnAccentColor:hover span, .btnOutlineStyle.btnAccentColor span:before, .btnFilledStyle.btnAccentColor:hover span:before, .btnOutlineStyle.btnAccentColor a, .btnFilledStyle.btnAccentColor:hover a, .btnOutlineStyle.btnAccentColor .btIco a:before, .btnFilledStyle.btnAccentColor:hover .btIco a:before, .btnOutlineStyle.btnAccentColor button, .btnFilledStyle.btnAccentColor:hover button{color: #58a0d3 !important;} .btnBorderlessStyle.btnAccentColor span, .btnBorderlessStyle.btnNormalColor:hover span, .btnBorderlessStyle.btnAccentColor span:before, .btnBorderlessStyle.btnNormalColor:hover span:before, .btnBorderlessStyle.btnAccentColor a, .btnBorderlessStyle.btnNormalColor:hover a, .btnBorderlessStyle.btnAccentColor .btIco a:before, .btnBorderlessStyle.btnNormalColor:hover .btIco a:before, .btnBorderlessStyle.btnAccentColor button, .btnBorderlessStyle.btnNormalColor:hover button{color: #58a0d3;} .btnFilledStyle.btnAlternateColor, .btnOutlineStyle.btnAlternateColor:hover{background-color: #1a86d3; border: 2px solid #1a86d3;} .btnOutlineStyle.btnAlternateColor, .btnFilledStyle.btnAlternateColor:hover{ border: 2px solid #1a86d3; color: #1a86d3;} .btnOutlineStyle.btnAlternateColor span, .btnFilledStyle.btnAlternateColor:hover span, .btnOutlineStyle.btnAlternateColor span:before, .btnFilledStyle.btnAlternateColor:hover span:before, .btnOutlineStyle.btnAlternateColor a, .btnFilledStyle.btnAlternateColor:hover a, .btnOutlineStyle.btnAlternateColor .btIco a:before, .btnFilledStyle.btnAlternateColor:hover .btIco a:before, .btnOutlineStyle.btnAlternateColor button, .btnFilledStyle.btnAlternateColor:hover button{color: #1a86d3 !important;} .btnBorderlessStyle.btnAlternateColor span, .btnBorderlessStyle.btnAlternateColor span:before, .btnBorderlessStyle.btnAlternateColor a, .btnBorderlessStyle.btnAlternateColor .btIco a:before, .btnBorderlessStyle.btnAlternateColor button{color: #1a86d3;} .btCounterHolder{font-family: "Montserrat";} .btCounterHolder .btCountdownHolder .days_text, .btCounterHolder .btCountdownHolder .hours_text, .btCounterHolder .btCountdownHolder .minutes_text, .btCounterHolder .btCountdownHolder .seconds_text{ font-family: Montserrat; color: #58a0d3;} .btProgressContent{font-family: "Montserrat";} .btProgressContent .btProgressAnim{ background-color: #58a0d3;} .btShowTitle{ border-left: 4px solid #58a0d3;} .btAccentColorBackground .btShowTitle{border-left: 4px solid #1a86d3;} .btPriceTable .btPriceTableHeader{background: #58a0d3;} .btPriceTableSticker{ font-family: "Montserrat";} .header .btSuperTitle{font-family: "Montserrat";} .header .btSubTitle{font-family: "Roboto";} .btDash.bottomDash .dash:after{ border-bottom: 4px solid #58a0d3;} .btDash.topDash .btSuperTitle:after, .btDash.topDash .btSuperTitle:before{ border-top: 1px solid #58a0d3;} .btNoMore{ font-family: Montserrat;} .btGridContent .header .btSuperTitle a:hover{color: #58a0d3;} .btCatFilter{ font-family: Montserrat;} .btCatFilter .btCatFilterItem:hover{color: #58a0d3;} .btCatFilter .btCatFilterItem.active{color: #58a0d3;} .nbs a .nbsItem .nbsDir{ font-family: "Montserrat";} .btLightSkin .btSimpleArrows .nbs a:hover:before, .btDarkSkin .btLightSkin .btSimpleArrows .nbs a:hover:before, .btLightSkin .btDarkSkin .btLightSkin .btSimpleArrows .nbs a:hover:before, .btDarkSkin .btSimpleArrows .nbs a:hover:before, .btLightSkin .btDarkSkin .btSimpleArrows .nbs a:hover:before, .btDarkSkin.btLightSkin .btDarkSkin .btSimpleArrows .nbs a:hover:before{color: #58a0d3 !important;} .neighboringArticles .nbs a .nbsItem .nbsDir{ font-family: 'Roboto',arial,sans-serif;} .neighboringArticles .nbs a:hover .nbsDir{color: #58a0d3;} .recentTweets small:before{ color: #58a0d3;} .btInfoBar .btInfoBarMeta p strong{color: #58a0d3;} .tabsHeader li{ font-family: "Montserrat";} .tabsVertical .tabAccordionTitle{ font-family: "Montserrat";} .btVisualizer{font-family: Montserrat;} form.wpcf7-form .wpcf7-submit{ background-color: #58a0d3;} .btAnimNav li.btAnimNavDot{ font-family: Montserrat;} .btAnimNav li.btAnimNavNext:hover, .btAnimNav li.btAnimNavPrev:hover{border-color: #58a0d3; color: #58a0d3;} .headline b.animate.animated{ color: #58a0d3;} .headline em.animate{ font-family: Roboto;} p.demo_store{ background-color: #58a0d3;} .woocommerce .woocommerce-info a: not(.button), .woocommerce .woocommerce-message a: not(.button), .woocommerce-page .woocommerce-info a: not(.button), .woocommerce-page .woocommerce-message a: not(.button){color: #58a0d3;} .woocommerce .woocommerce-message:before, .woocommerce .woocommerce-info:before, .woocommerce-page .woocommerce-message:before, .woocommerce-page .woocommerce-info:before{ color: #58a0d3;} .woocommerce a.button, .woocommerce input[type="submit"], .woocommerce button[type="submit"], .woocommerce input.button, .woocommerce input.alt:hover, .woocommerce a.button.alt:hover, .woocommerce .button.alt:hover, .woocommerce button.alt:hover, .woocommerce-page a.button, .woocommerce-page input[type="submit"], .woocommerce-page button[type="submit"], .woocommerce-page input.button, .woocommerce-page input.alt:hover, .woocommerce-page a.button.alt:hover, .woocommerce-page .button.alt:hover, .woocommerce-page button.alt:hover{ font-family: Montserrat;} .woocommerce a.button:hover, .woocommerce input[type="submit"]:hover, .woocommerce .button:hover, .woocommerce button:hover, .woocommerce input.alt, .woocommerce a.button.alt, .woocommerce .button.alt, .woocommerce button.alt, .woocommerce-page a.button:hover, .woocommerce-page input[type="submit"]:hover, .woocommerce-page .button:hover, .woocommerce-page button:hover, .woocommerce-page input.alt, .woocommerce-page a.button.alt, .woocommerce-page .button.alt, .woocommerce-page button.alt{ font-family: "Montserrat";} .woocommerce p.lost_password:before, .woocommerce-page p.lost_password:before{ color: #58a0d3;} .woocommerce form.login p.lost_password a:hover, .woocommerce-page form.login p.lost_password a:hover{color: #58a0d3;} .woocommerce .added:after, .woocommerce .loading:after, .woocommerce-page .added:after, .woocommerce-page .loading:after{ background-color: #58a0d3;} .woocommerce form .form-row .select2-container, .woocommerce-page form .form-row .select2-container{ font-family: "Montserrat";} .woocommerce div.product p.price, .woocommerce div.product span.price, .woocommerce-page div.product p.price, .woocommerce-page div.product span.price{ font-family: "Montserrat"; color: #58a0d3;} .woocommerce div.product .stock, .woocommerce-page div.product .stock{color: #58a0d3;} .woocommerce div.product a.reset_variations:hover, .woocommerce-page div.product a.reset_variations:hover{color: #58a0d3;} .woocommerce .added_to_cart, .woocommerce-page .added_to_cart{ font-family: Montserrat;} .woocommerce .products ul li.product .btPriceTableSticker, .woocommerce ul.products li.product .btPriceTableSticker, .woocommerce-page .products ul li.product .btPriceTableSticker, .woocommerce-page ul.products li.product .btPriceTableSticker{ background: #1a86d3;} .woocommerce .products ul li.product .price, .woocommerce ul.products li.product .price, .woocommerce-page .products ul li.product .price, .woocommerce-page ul.products li.product .price{ font-family: "Montserrat";} .woocommerce nav.woocommerce-pagination, .woocommerce-page nav.woocommerce-pagination{ font-family: "Montserrat";} .woocommerce nav.woocommerce-pagination ul li a:focus, .woocommerce nav.woocommerce-pagination ul li a:hover, .woocommerce nav.woocommerce-pagination ul li a.next, .woocommerce nav.woocommerce-pagination ul li a.prev, .woocommerce nav.woocommerce-pagination ul li span.current, .woocommerce-page nav.woocommerce-pagination ul li a:focus, .woocommerce-page nav.woocommerce-pagination ul li a:hover, .woocommerce-page nav.woocommerce-pagination ul li a.next, .woocommerce-page nav.woocommerce-pagination ul li a.prev, .woocommerce-page nav.woocommerce-pagination ul li span.current{background: #58a0d3;} .woocommerce .star-rating span:before, .woocommerce-page .star-rating span:before{ color: #58a0d3;} .woocommerce p.stars a[class^="star-"].active:after, .woocommerce p.stars a[class^="star-"]:hover:after, .woocommerce-page p.stars a[class^="star-"].active:after, .woocommerce-page p.stars a[class^="star-"]:hover:after{color: #58a0d3;} .woocommerce-cart table.cart td.product-remove a.remove{ color: #58a0d3; border: 1px solid #58a0d3;} .woocommerce-cart table.cart td.product-remove a.remove:hover{background-color: #58a0d3;} .woocommerce-cart .cart_totals .discount td{color: #58a0d3;} .woocommerce-account header.title .edit{ color: #58a0d3;} .woocommerce-account header.title .edit:before{ color: #58a0d3;} .btLightSkin.woocommerce-page .product .headline a:hover, .btDarkSkin .btLightSkin.woocommerce-page .product .headline a:hover, .btLightSkin .btDarkSkin .btLightSkin.woocommerce-page .product .headline a:hover, .btDarkSkin.woocommerce-page .product .headline a:hover, .btLightSkin .btDarkSkin.woocommerce-page .product .headline a:hover, .btDarkSkin.btLightSkin .btDarkSkin.woocommerce-page .product .headline a:hover{color: #58a0d3;} .btQuoteBooking .btTotalNextWrapper{ font-family: "Montserrat";} .btQuoteBooking .btContactNext{ border: #58a0d3 2px solid; color: #58a0d3;} .btQuoteBooking .btContactNext:hover, .btQuoteBooking .btContactNext:active{background-color: #58a0d3 !important;} .btQuoteBooking .btQuoteSwitch:hover{-webkit-box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btQuoteSwitch.on .btQuoteSwitchInner{ background: #58a0d3;} .btQuoteBooking .dd.ddcommon.borderRadiusTp .ddTitleText, .btQuoteBooking .dd.ddcommon.borderRadiusBtm .ddTitleText{ -webkit-box-shadow: 5px 0 0 #58a0d3 inset,0 2px 10px rgba(0,0,0,.2); box-shadow: 5px 0 0 #58a0d3 inset,0 2px 10px rgba(0,0,0,.2);} .btQuoteBooking .ui-slider .ui-slider-handle{ background: #58a0d3;} .btQuoteBooking .btQuoteBookingForm .btQuoteTotal{ background: #58a0d3;} .btQuoteBooking .btContactFieldMandatory.btContactFieldError input, .btQuoteBooking .btContactFieldMandatory.btContactFieldError textarea{border: 1px solid #58a0d3; -webkit-box-shadow: 0 0 0 1px #58a0d3 inset; box-shadow: 0 0 0 1px #58a0d3 inset;} .btQuoteBooking .btContactFieldMandatory.btContactFieldError .dd.ddcommon.borderRadius .ddTitleText{border: 1px solid #58a0d3; -webkit-box-shadow: 0 0 0 1px #58a0d3 inset; box-shadow: 0 0 0 1px #58a0d3 inset;} .btQuoteBooking .btContactFieldMandatory.btContactFieldError input:hover, .btQuoteBooking .btContactFieldMandatory.btContactFieldError textarea:hover{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btContactFieldMandatory.btContactFieldError .dd.ddcommon.borderRadius:hover .ddTitleText{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btContactFieldMandatory.btContactFieldError input:focus, .btQuoteBooking .btContactFieldMandatory.btContactFieldError textarea:focus{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btContactFieldMandatory.btContactFieldError .dd.ddcommon.borderRadiusTp .ddTitleText{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btSubmitMessage{color: #58a0d3;} .btDatePicker .ui-datepicker-header{ background-color: #58a0d3;} .btQuoteBooking .btContactSubmit{font-family: "Montserrat"; background-color: #58a0d3; border: 1px solid #58a0d3;} .btQuoteBooking .btContactSubmit:hover{ color: #58a0d3;} .btPayPalButton:hover{-webkit-box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} #btSettingsPanel #btSettingsPanelToggler:before{ color: #58a0d3;} #btSettingsPanel h4{ background-color: #58a0d3;} #btSettingsPanel .btSettingsPanelRow.btAccentColorRow .trigger, #btSettingsPanel .btSettingsPanelRow.btAccentColorRow select{border-color: #58a0d3;} #btSettingsPanel .btSettingsPanelRow.btAlternateColorRow .trigger, #btSettingsPanel .btSettingsPanelRow.btAlternateColorRow select{border-color: #1a86d3;} .wp-block-button__link:hover{color: #58a0d3 !important;}
.tagcloud a { color: #ffffff; } .btTopToolsInMenuArea.btMenuHorizontal .topTools .btAccentIconWidget, .btTopToolsInMenuArea.btMenuHorizontal .topBarInMenu .btAccentIconWidget { background-color: #02b3f9; }</style>
<link rel="stylesheet" id="industrial-print-css" href="./../../../../wp-content/themes/industrial/print.css?ver=5.8" type="text/css" media="print">
<style id="elementor-frontend-inline-css" type="text/css">@font-face{font-family:eicons;src:url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.eot?5.10.0);src:url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.eot?5.10.0#iefix) format("embedded-opentype"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.woff2?5.10.0) format("woff2"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.woff?5.10.0) format("woff"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.ttf?5.10.0) format("truetype"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.svg?5.10.0#eicon) format("svg");font-weight:400;font-style:normal}</style>
<style id="font-awesome-official-v4shim-inline-css" type="text/css">@font-face {
font-family: "FontAwesome";
font-display: block;
src: url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.eot"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.eot?#iefix") format("embedded-opentype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.woff2") format("woff2"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.woff") format("woff"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.ttf") format("truetype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.svg#fontawesome") format("svg");
}

@font-face {
font-family: "FontAwesome";
font-display: block;
src: url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.eot"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.eot?#iefix") format("embedded-opentype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.woff2") format("woff2"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.woff") format("woff"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.ttf") format("truetype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.svg#fontawesome") format("svg");
}

@font-face {
font-family: "FontAwesome";
font-display: block;
src: url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.eot"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.eot?#iefix") format("embedded-opentype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.woff2") format("woff2"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.woff") format("woff"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.ttf") format("truetype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.svg#fontawesome") format("svg");
unicode-range: U+F004-F005,U+F007,U+F017,U+F022,U+F024,U+F02E,U+F03E,U+F044,U+F057-F059,U+F06E,U+F070,U+F075,U+F07B-F07C,U+F080,U+F086,U+F089,U+F094,U+F09D,U+F0A0,U+F0A4-F0A7,U+F0C5,U+F0C7-F0C8,U+F0E0,U+F0EB,U+F0F3,U+F0F8,U+F0FE,U+F111,U+F118-F11A,U+F11C,U+F133,U+F144,U+F146,U+F14A,U+F14D-F14E,U+F150-F152,U+F15B-F15C,U+F164-F165,U+F185-F186,U+F191-F192,U+F1AD,U+F1C1-F1C9,U+F1CD,U+F1D8,U+F1E3,U+F1EA,U+F1F6,U+F1F9,U+F20A,U+F247-F249,U+F24D,U+F254-F25B,U+F25D,U+F267,U+F271-F274,U+F279,U+F28B,U+F28D,U+F2B5-F2B6,U+F2B9,U+F2BB,U+F2BD,U+F2C1-F2C2,U+F2D0,U+F2D2,U+F2DC,U+F2ED,U+F328,U+F358-F35B,U+F3A5,U+F3D1,U+F410,U+F4AD;
}</style>
<script  data-rocket-type="text/javascript" src="./../../../../wp-includes/js/jquery/jquery.min.js?ver=3.6.0" id="jquery-core-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-includes/js/jquery/jquery-migrate.min.js?ver=3.3.2" id="jquery-migrate-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/bold-page-builder/script_fe.js?ver=1620657753" id="bt_bb_fe-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/bt_elements.js?ver=1620657753" id="bt_plugin_enqueue-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/modal-for-elementor/js/jquery.cookie.js?ver=1620657753" id="jquery-cookie-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/html5shiv.min.js?ver=1" id="html5shiv-min-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/respond.min.js?ver=1" id="respond-min-js" defer></script>
<script  data-rocket-type="text/javascript" id="industrial-header-misc-js-before">
window.BoldThemesURI = "./wp-content/themes/industrial"; window.BoldThemesAJAXURL = "./wp-admin/admin-ajax.php";window.boldthemes_text = [];window.boldthemes_text.previous = 'previous';window.boldthemes_text.next = 'next';
</script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/header.misc.js?ver=1620657753" id="industrial-header-misc-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/sticky-header-effects-for-elementor/assets/js/she-header.js?ver=1620657753" id="she-header-js" defer></script>
<link rel="https://api.w.org/" href="./../../../../wp-json/index.html">
<link rel="alternate" type="application/json" href="./../../../../wp-json/wp/v2/pages/3408/index.html">
<meta name="generator" content="WordPress 5.8">
<link rel="shortlink" href="./../../../../index.html?p=3408">
<link rel="alternate" type="application/json+oembed" href="./../../../../wp-json/oembed/1.0/embed/index.html?url=https%3A%2F%2F%2Factive-pharmaceutical-ingredients%2F">
<link rel="alternate" type="text/xml+oembed" href="./../../../../wp-json/oembed/1.0/embed/index.html?url=https%3A%2F%2F%2Factive-pharmaceutical-ingredients%2F&#038;format=xml">
<script  data-rocket-type="text/javascript">
            ( function () {
                window.lae_fs = { can_use_premium_code: false};
            } )();
        </script>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Productivity.woff?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Development.ttf?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Construction.ttf?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/CraftEssential.ttf?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Pe-icon-7-stroke.woff?d7yf1v" crossorigin>
<link rel="icon" href="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-32x32.jpg" sizes="32x32">
<link rel="icon" href="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-192x192.jpg" sizes="192x192">
<link rel="apple-touch-icon" href="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-180x180.jpg">
<meta name="msapplication-TileImage" content="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-270x270.jpg">
<noscript><style id="rocket-lazyload-nojs-css">.rll-youtube-player, [data-lazy-src]{display:none !important;}</style></noscript>

<script  async src="https://www.googletagmanager.com/gtag/js?id=UA-124610061-1"></script>
<script >
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'UA-124610061-1');
	
</script>

<script  async src="https://www.googletagmanager.com/gtag/js?id=AW-634803173"></script>
<script >
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'AW-634803173');
</script>

<script >
  gtag('event', 'conversion', {'send_to': 'AW-634803173/aDeACK-KstABEOWn2a4C'});
</script>

<script >(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-KJ8SPBQ');</script>

<script async src="./../../../../cdn-cgi/bm/cv/669835187/api.js"></script>
</head>
<body class="page-template-default page page-id-3408 bt_bb_plugin_active bt_bb_fe_preview_toggle has-navmenu has-megamenu bodyPreloader btMenuLeftEnabled btMenuBelowLogo btStickyEnabled btHideHeadline btLightSkin btTopToolsInMenuArea btRemovePreloader btSoftRoundedButtons btLightAlternateHeader btNoSidebar cookies-not-set elementor-default elementor-kit-3445 elementor-page elementor-page-3408" data-autoplay="0">

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KJ8SPBQ" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>

<div class="btPageWrap" id="top">
<header class="mainHeader btClear gutter ">
<div class="port">
<div class="btLogoArea menuHolder btClear">
<span class="btVerticalMenuTrigger">&nbsp;<span class="btIco btIcoDefaultType"><a href="#" target="_self" data-ico-fa="&#xf0c9;" class="btIcoHolder"></a></span></span>
<span class="btHorizontalMenuTrigger">&nbsp;<span class="btIco btIcoDefaultType"><a href="#" target="_self" data-ico-fa="&#xf0c9;" class="btIcoHolder"></a></span></span>
<div class="logo">
<span>
<a href="./../../../../index.html"><img class="btMainLogo" data-hw="1" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ikigai&reg; Corporation" data-lazy-src="./../../../../wp-content/uploads/2020/05/logo-2.png"><noscript><img class="btMainLogo" data-hw="1" src="./../../../../wp-content/uploads/2020/05/logo-2.png" alt="Ikigai&reg; Corporation"></noscript>
<img class="btAltLogo" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ikigai&reg; Corporation" data-lazy-src="./../../../../wp-content/uploads/2018/10/cropped-imgonline-com-ua-Compressed-09lij2UbRT-com.jpg"><noscript><img class="btAltLogo" src="./../../../../wp-content/uploads/2018/10/cropped-imgonline-com-ua-Compressed-09lij2UbRT-com.jpg" alt="Ikigai&reg; Corporation"></noscript></a> </span>
</div>
<div class="topBarInLogoArea">
<div class="topBarInLogoAreaCell">
<span class="btIconWidget btAccentIconWidget btWidgetWithText"><span class="btIconWidgetIcon"><span class="btIco btIcoDefaultType btIcoDefaultColor"><span data-ico-pr="&#xf10f;" class="btIcoHolder"></span></span></span><span class="btIconWidgetContent"><span class="btIconWidgetTitle">Working hours:</span><span class="btIconWidgetText">Mon - Fri 9.00 - 18.00</span></span></span> </div>
</div>
</div>
<div class="btBelowLogoArea btClear"> <div class="menuPort">
<div class="topBarInMenu">
<div class="topBarInMenuCell">
<span id="time610e3a31c10e7" class="btIconWidget"><span class="btIconWidgetIcon"><span class="btIco btIcoDefaultType btIcoDefaultColor"><span data-ico-fa="&#xf017;" class="btIcoHolder"></span></span></span><span class="btIconWidgetContent"><span class="btIconWidgetTitle">Hong Kong time</span><span class="btIconWidgetText"></span></span></span><div class="btTopBox widget_search">
<h2 class="widgettitle">Search</h2>
<div class="btSearch">
<span class="btIco btIcoDefaultType btIcoDefaultColor"><a href="#" target="_self" data-ico-fa="&#xf002;" class="btIcoHolder" style="color:#fff"></a></span>
<div class="btSearchInner gutter" role="search">
<div class="btSearchInnerContent port">
 <form action="./index.html" method="get">
<div class="col-lg-12 form-control-group"><input type="text" id="elastic"placeholder="Looking for..."></div>
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../portfolio/azithromycin/"style="
    color: #fff;
"><li class="hide">Azithromycin</li></a>
	<a href="./../portfolio/doxycycline/"style="
    color: #fff;
"><li class="hide">Doxycycline</li></a>
	<a href="./../portfolio/levofloxacin/"style="
    color: #fff;
"><li class="hide">Levofloxacin</li></a>
	<a href="./../portfolio/metronidazole/"style="
    color: #fff;
"><li class="hide">Metronidazole</li></a>
	<a href="./../portfolio/trimethoprim/"style="
    color: #fff;
"><li class="hide">Trimethoprim</li></a>
	<a href="./../portfolio/sulfamethoxazole/"style="
    color: #fff;
"><li class="hide">Sulfamethoxazole</li></a>
	<a href="./../portfolio/ciprofloxacin/"style="
    color: #fff;
"><li class="hide">Ciprofloxacin</li></a>
	<a href="./../portfolio/cephalexin/"style="
    color: #fff;
"><li class="hide">Cephalexin</li></a>
	<a href="./../portfolio/clindamycin/"style="
    color: #fff;
"><li class="hide">Clindamycin</li></a>
	<a href="./../portfolio/clavulanic-acid/"style="
    color: #fff;
"><li class="hide">Clavulanic acid</li></a>



</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../portfolio/amoxicillin/"style="
    color: #fff;
"><li class="hide">Amoxicillin</li></a>
	<a href="./../portfolio/boldenone-cypionate/"style="
    color: #fff;
"><li class="hide">Boldenone cypionate</li></a>
	<a href="./../portfolio/boldenone-propionate/"style="
    color: #fff;
"><li class="hide">Boldenone propionate</li></a>
	<a href="./../portfolio/boldenone-acetate/"style="
    color: #fff;
"><li class="hide">Boldenone acetate</li></a>
	<a href="./../portfolio/boldenone-undecylenate/"style="
    color: #fff;
"><li class="hide">Boldenone undecylenate</li></a>
	<a href="./../portfolio/boldenone/"style="
    color: #fff;
"><li class="hide">Boldenone</li></a>
	<a href="./../portfolio/spironolactone/"style="
    color: #fff;
"><li class="hide">Spironolactone</li></a>
	<a href="./../portfolio/11a-hydroxy-canrenone/"style="
    color: #fff;
"><li class="hide">11a Hydroxy Canrenone</li></a>
	<a href="./../portfolio/canrenone/"style="
    color: #fff;
"><li class="hide">Canrenone</li></a>
	<a href="./../portfolio/prednisolone-acetate/"style="
    color: #fff;
"><li class="hide">Prednisolone acetate</li></a>



</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../portfolio/prednisolone/"style="
    color: #fff;
"><li class="hide">Prednisolone</li></a>
	<a href="./../portfolio/anecortave-acetate/"style="
    color: #fff;
"><li class="hide">Anecortave acetate</li></a>
	<a href="./../portfolio/prednisone-acetate/"style="
    color: #fff;
"><li class="hide">Prednisone acetate</li></a>
	<a href="./../portfolio/prednisone/"style="
    color: #fff;
"><li class="hide">Prednisone</li></a>
	<a href="./../portfolio/hydrocortisone-acetate/"style="
    color: #fff;
"><li class="hide">Hydrocortisone Acetate</li></a>
	<a href="./../portfolio/hydrocortisone/"style="
    color: #fff;
"><li class="hide">Hydrocortisone</li></a>
	<a href="./../portfolio/cortisone-acetate/"style="
    color: #fff;
"><li class="hide">Cortisone Acetate</li></a>
	<a href="./../portfolio/cortisone/"style="
    color: #fff;
"><li class="hide">Cortisone</li></a>
	<a href="./../portfolio/7-keto-dhea/"style="
    color: #fff;
"><li class="hide">7-Keto DHEA</li></a>
	<a href="./../portfolio/androstanolone/"style="
    color: #fff;
"><li class="hide">Androstanolone</li></a>
	


</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../portfolio/mestanolone/"style="
    color: #fff;
"><li class="hide">Mestanolone</li></a>
	<a href="./../portfolio/epiandrosterone/"style="
    color: #fff;
"><li class="hide">Epiandrosterone</li></a>
	<a href="./../portfolio/estradiol-valerate/"style="
    color: #fff;
"><li class="hide">Estradiol Valerate</li></a>
	<a href="./../portfolio/estradiol-cypionate/"style="
    color: #fff;
"><li class="hide">Estradiol Cypionate</li></a>
	<a href="./../portfolio/estradiol-enanthate/"style="
    color: #fff;
"><li class="hide">Estradiol Enanthate</li></a>
<a href="./../portfolio/estradiol-benzoate/"style="
    color: #fff;
"><li class="hide">Estradiol Benzoate</li></a>
	<a href="./../portfolio/estriol/"style="
    color: #fff;
"><li class="hide">Estriol</li></a>
	<a href="./../portfolio/estradiol/"style="
    color: #fff;
"><li class="hide">Estradiol</li></a>
	<a href="./../portfolio/estrone/"style="
    color: #fff;
"><li class="hide">Estrone</li></a>
	<a href="./../portfolio/dehydronandrolone-acetate/"style="
    color: #fff;
"><li class="hide">Dehydronandrolone Acetate</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../portfolio/nandrolone-undecanoate/"style="
    color: #fff;
"><li class="hide">Nandrolone Undecanoate</li></a>
	<a href="./../portfolio/nandrolone-cypionate/"style="
    color: #fff;
"><li class="hide">Nandrolone Cypionate</li></a>
	<a href="./../portfolio/nandrolone-propionate/"style="
    color: #fff;
"><li class="hide">Pandrolone Propionate</li></a>
	<a href="./../portfolio/nandrolone-phenylpropionate/"style="
    color: #fff;
"><li class="hide">Nandrolone Phenylpropionate</li></a>
	<a href="./../portfolio/nandrolone-decanoate/"style="
    color: #fff;
"><li class="hide">Nandrolone Decanoate</li></a>
<a href="./../portfolio/nandrolone-base-（19-nor-testosterone）/"style="
    color: #fff;
"><li class="hide">Nandrolone</li></a>
	<a href="./../portfolio/drostanolone-enanthate/"style="
    color: #fff;
"><li class="hide">Drostanolone Enanthate</li></a>
	<a href="./../portfolio/drostanolone-propionate/"style="
    color: #fff;
"><li class="hide">Drostanolone Propionate</li></a>
	<a href="./../portfolio/metenolone-acetate/"style="
    color: #fff;
"><li class="hide">Metenolone Acetate</li></a>
	<a href="./../portfolio/trenbolone-enanthate/"style="
    color: #fff;
"><li class="hide">Trenbolone Enanthate</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../portfolio/trenbolone-acetate/"style="
    color: #fff;
"><li class="hide">Trenbolone Acetate</li></a>
	<a href="./../portfolio/fluoxymesterone/"style="
    color: #fff;
"><li class="hide">Fluoxymesterone</li></a>
	<a href="./../portfolio/mesterolone/"style="
    color: #fff;
"><li class="hide">Mesterolone</li></a>
<a href="./../portfolio/altrenogest//"style="
    color: #fff;
"><li class="hide">Altrenogest</li></a>
	<a href="./../portfolio/exemestane/"style="
    color: #fff;
"><li class="hide">Exemestane</li></a>
	<a href="./../portfolio/oxandrolone/"style="
    color: #fff;
"><li class="hide">Oxandrolone</li></a>
	<a href="./../portfolio/methandienone/"style="
    color: #fff;
"><li class="hide">Methandienone</li></a>
	<a href="./../portfolio/oxymetholone/"style="
    color: #fff;
"><li class="hide">Oxymetholone</li></a>
	<a href="./../portfolio/stanozolol/"style="
    color: #fff;
"><li class="hide">Stanozolol</li></a>
	<a href="./../portfolio/methenolone-enanthate/"style="
    color: #fff;
"><li class="hide">Methenolone Enanthate</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../portfolio/progesterone/"style="
    color: #fff;
"><li class="hide">Progesterone</li></a>
	<a href="./../portfolio/20-formylpregn-4-en-3-one/"style="
    color: #fff;
"><li class="hide">20-Formylpregn-4-en-3-one</li></a>
	<a href="./../portfolio/14-androstadienedioneadd/"style="
    color: #fff;
"><li class="hide">1,4-Androstadienedione(add)</li></a>
	<a href="./../portfolio/4-androstenedione4-ad/"style="
    color: #fff;
"><li class="hide">4-Androstenedione (4-AD)</li></a>
	<a href="./../portfolio/1-testosterone/"style="
    color: #fff;
"><li class="hide">1-Testosterone</li></a>
	<a href="./../portfolio/methyl-1-testosterone/"style="
    color: #fff;
"><li class="hide">Methyl-1-Testosterone</li></a>
	<a href="./../portfolio/testosterone-undecanoate/"style="
    color: #fff;
"><li class="hide">Testosterone Undecanoate</li></a>
	<a href="./../portfolio/testosterone-isocaproate/"style="
    color: #fff;
"><li class="hide">Testosterone Isocaproate</li></a>
	<a href="./../portfolio/testosterone-propionate/"style="
    color: #fff;
"><li class="hide">Testosterone Propionate</li></a>
	<a href="./../portfolio/testosterone-phenylpropionate/"style="
    color: #fff;
"><li class="hide">Testosterone Phenylpropionate</li></a>



</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../portfolio/sitolactone/"style="
    color: #fff;
"><li class="hide">Sitolactone</li></a>
	<a href="./../portfolio/testosterone-enanthate/"style="
    color: #fff;
"><li class="hide">Testosterone Enanthate</li></a>
	<a href="./../portfolio/testosterone-decanoate/"style="
    color: #fff;
"><li class="hide">Testosterone Decanoate</li></a>
	<a href="./../portfolio/testosterone-cypionate/"style="
    color: #fff;
"><li class="hide">Testosterone Cypionate</li></a>
	<a href="./../portfolio/testosterone-acetate/"style="
    color: #fff;
"><li class="hide">Testosterone Acetate</li></a>
	<a href="./../portfolio/methyltestosterone/"style="
    color: #fff;
"><li class="hide">Methyltestosterone</li></a>
	<a href="./../portfolio/testosterone/"style="
    color: #fff;
"><li class="hide">Testosterone</li></a>
	<a href="./../portfolio/magnesium-stearate/"style="
    color: #fff;
"><li class="hide">Magnesium Stearate</li></a>
	<a href="./../portfolio/bis4-nitrophenylsulfane/"style="
    color: #fff;
"><li class="hide">Bis(4-nitrophenylsulfane)</li></a>
	<a href="./../portfolio/n-benzhydrylpiperazine/"style="
    color: #fff;
"><li class="hide">N-Benzhydrylpiperazine</li></a>

	



</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	
<a href="./../portfolio/zinc-stearate/"style="
    color: #fff;
"><li class="hide">Zinc stearate</li></a>
	<a href="./../portfolio/sodium-starch-glycolate/"style="
    color: #fff;
"><li class="hide">Sodium starch glycolate</li></a>
	<a href="./../portfolio/microcrystalline-cellulose/"style="
    color: #fff;
"><li class="hide">microcrystalline Cellulose</li></a>
	<a href="./../portfolio/croscarmellose-sodium/"style="
    color: #fff;
"><li class="hide">CROSCARMELLOSE SODIUM</li></a>
	<a href="./../portfolio/calcium-stearate/"style="
    color: #fff;
"><li class="hide">Calcium stearate</li></a>
	<a href="./../portfolio/calcium-lactate/"style="
    color: #fff;
"><li class="hide">Calcium lactate</li></a>
	<a href="./../portfolio/calcium-acetate/"style="
    color: #fff;
"><li class="hide">Calcium acetate</li></a>
	<a href="./../portfolio/1-aminoindan/"style="
    color: #fff;
"><li class="hide">1-Aminoindan</li></a>
	<a href="./../portfolio/44-sulfonylbisnitrobenzene/"style="
    color: #fff;
"><li class="hide">4,4′-sulfonylbis(nitrobenzene)</li></a>
	<a href="./../portfolio/dehydroepiandrosterone-enanthate/"style="
    color: #fff;
"><li class="hide">Dehydroepiandrosterone Enanthate</li></a>




</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../portfolio/11a17a-dihydroxyprogesterone/"style="
    color: #fff;
"><li class="hide">11a,17a-Dihydroxyprogesterone</li></a>
	<a href="./../portfolio/17a-hydroxyprogesterone-hpg/"style="
    color: #fff;
"><li class="hide">17a-Hydroxyprogesterone (HPG)</li></a>
    <a href="./../portfolio/dehydroepiandrosterone-acetate-prasterone-acetate/"style="
    color: #fff;
"><li class="hide">Dehydroepiandrosterone Acetate Prasterone Acetate</li></a>
	<a href="./../portfolio/dehydroepiandrosterone-dheaprasterone/"style="
    color: #fff;
"><li class="hide">Dehydroepiandrosterone DHEA, Prasterone</li></a>
	<a href="./../portfolio/trenbolone-cyclohexylmethylcarbonate/"style="
    color: #fff;
"><li class="hide">Trenbolone Cyclohexylmethylcarbonate</li></a>
	<a href="./../portfolio/4-chlorodehydromethyltestosterone/"style="
    color: #fff;
"><li class="hide">4-Chlorodehydromethyltestosterone</li></a>
	<a href="./../portfolio/21-hydroxy-20-methylpregn-4-en-3-one/"style="
    color: #fff;
"><li class="hide">21-Hydroxy-20-methylpregn-4-en-3-one</li></a>
	<a href="./../portfolio/9a-hydroxy-4-androstenedione-（9a-ohad）/"style="
    color: #fff;
"><li class="hide">9a-Hydroxy-4-androstenedione（9a-OHAD)</li></a>
	<a href="./../portfolio/44-difluorobenzhydrylpiperazine/"style="
    color: #fff;
"><li class="hide">4,4′-Difluorobenzhydrylpiperazine</li></a>
	<a href="./../portfolio/ethyl-6-4-iodophenyl-1/"style="
    color: #fff;
"><li class="hide">Ethyl 6-(4-iodophenyl)-1-(4-methoxy phenyl)-7- oxo-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4- c]pyridine-3-carboxylate</li></a>
	



</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
		<a href="./../portfolio/ethyl-1-4-methoxyphenyl-7/"style="
    color: #fff;
"><li class="hide">Ethyl 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro1H-pyrazolo[3,4-c]pyridine-3-carboxylate</li></a>
		<a href="./../portfolio/5-bromo-2-chloro4ethoxydiphenylmethane/"style="
    color: #fff;
"><li class="hide">5-Bromo-2-chloro4’ethoxydiphenylmethane</li></a>
	<a href="./../portfolio/15-anhydro-1-c-4-chloro-3/"style="
    color: #fff;
"><li class="hide">1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-,2,3,4,6-tetraacetate, (1S)- D-Glucitol</li></a>
	<a href="./../portfolio/2346-tetra-o-trimethylsilyl-s-d-glucolactone/"style="
    color: #fff;
"><li class="hide">2,3,4,6-tetra-O-trimethylsilyl-ß-D-glucolactone</li></a>
	<a href="./../portfolio/carbamic-acid-n-1s2r/"style="
    color: #fff;
"><li class="hide">Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1- (phenylmethyl)propyl]-,1,1-dimethylethylester</li></a>
	<a href="./../portfolio/10s-1011-dihydro-10-hydroxy/"style="
    color: #fff;
"><li class="hide">(10S)-10,11-Dihydro-10-hydroxy-5Hdibenz[b,f]azepine-5-carboxamide</li></a>
	<a href="./../portfolio/1011-dihydro-10-hydroxy-5h/"style="
    color: #fff;
"><li class="hide">10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide</li></a>
	<a href="./../portfolio/3-3-dichloro-1-4-iodophenyl-piperidin-2-one/"style="
    color: #fff;
"><li class="hide">3, 3-dichloro-1-(4-iodophenyl) piperidin-2-one</li></a>
	<a href="./../portfolio/1-23-dichlorophenyl-piperazine/"style="
    color: #fff;
"><li class="hide">1-(2,3-Dichlorophenyl) Piperazine HCl</li></a>
	<a href="./../portfolio/1e-n-hydroxy-5-methoxy-1/"style="
    color: #fff;
"><li class="hide">(1E)-N-Hydroxy-5-Methoxy-1-(4-Trifluoromethylphenyl)Pentan-1-Imine</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../portfolio/2-bromo-4-benzyloxy-3-nitroacetophenone/"style="
    color: #fff;
"><li class="hide">2-Bromo-4′-benzyloxy-3′-nitroacetophenone</li></a>
	<a href="./../portfolio/24-dihydro-4-4-4-4-methoxyphenyl-1/"style="
    color: #fff;
"><li class="hide">2,4-Dihydro-4-[4-[4-(4-methoxyphenyl)-1- piperazinyl]phenyl]-2-(1-methyl propyl)-3H-1,2,4-triazol-3-one</li></a>
	<a href="./../portfolio/1-acetyl-4-4-hydroxyphenyl-piperazine/"style="
    color: #fff;
"><li class="hide">1-Acetyl-4-(4-hydroxyphenyl) piperazine</li></a>
	<a href="./../portfolio/1r-2-2-4-nitrophenylethylamino-1/"style="
    color: #fff;
"><li class="hide">(1R)-2-{[2-(4-nitrophenyl)ethyl]amino}-1-phenylethanol</li></a>
	<a href="./../portfolio/5-methylpyridin-21h-one-2-hydroxy-5/"style="
    color: #fff;
"><li class="hide">5-methylpyridin-2(1H)-one/2-Hydroxy-5- methylpyridine</li></a>
	<a href="./../portfolio/dibenzo-b-f-1-4-thiazepin-1110h-one/"style="
    color: #fff;
"><li class="hide">Dibenzo [b, f] [1, 4] thiazepin- 11(10H)-one</li></a>
	<a href="./../portfolio/4-4-5s-5-aminomethyl-2-oxo-13/"style="
    color: #fff;
"><li class="hide">4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one hydrochloride</li></a>
<a href="./../portfolio/2-5s-2-oxo-3-4-3-oxomorpholin-4-yl/"style="
    color: #fff;
"><li class="hide">2-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-1,3(2H)-dione</li></a>
	<a href="./../portfolio/2-3ar4s6r6as-6/"style="
    color: #fff;
"><li class="hide">2-(((3aR,4S,6R,6aS)-6-((5-amino-6-chlo ro-2-(propylthio)pyrimidin-4-yl)amino) -2,2-dimethyltetrahydro-3aH-cyclo penta[d][1,3]dioxol-4-yl)oxy)ethanol</li></a>
	<a href="./../portfolio/1-acetamido-35-dimethyl-adamantane/"style="
    color: #fff;
"><li class="hide">1-Acetamido 3,5-dimethyl Adamantane*</li></a>
	



</ul></div> 

</form>
<div class="btSearchInnerClose"><span class="btIco "><a href="#" target="_self" data-ico-fa="&#xf00d;" class="btIcoHolder" style="color:#fff"></a></span></div>
</div>
</div>
</div>
</div> </div>
</div>
<nav>
<ul id="menu-primary-menu" class="menu">
<li id="menu-item-3253" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-3253"><a title="						" href="./../../../../index.html">Home</a></li>
<li id="menu-item-3403" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3403">
<a href="./../../../../about-us/index.html">About us</a><ul class="sub-menu">
<li id="menu-item-3399" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3399"><a href="./../../../../about-us/index.html#company_profile">Company Profile/ Who we are?</a></li>
<li id="menu-item-3400" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3400"><a href="./../../../../about-us/index.html#vision&#038;values">Vision &#038; Values</a></li>
<li id="menu-item-3401" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3401"><a href="./../../../../about-us/index.html#business_segment">Business Segments</a></li>
<li id="menu-item-3402" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3402"><a href="./../../../../about-us/index.html#geographic_spread">Geographic spread</a></li>
</ul>
</li>
<li id="menu-item-3459" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3459"><a href="./../../../../our-technology/index.html">Our Technology</a></li>
<li id="menu-item-3256" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-ancestor current-menu-parent current_page_parent current_page_ancestor menu-item-has-children menu-item-3256">
<a title="						" href="./../../../../services/index.html">Product Portfolio</a><ul class="sub-menu">
<li id="menu-item-3415" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-3408 current_page_item menu-item-3415"><a href="./index.html" aria-current="page">Active pharmaceutical ingredients</a></li>
<li id="menu-item-3868" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3868"><a href="./../../../../pharmaceutical_intermediates/index.html">Pharmaceutical intermediates</a></li>
<li id="menu-item-3414" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3414"><a href="./../../../../pharmaceutical_excipients/index.html">Pharmaceutical excipients</a></li>
</ul>
</li>
<li id="menu-item-3872" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3872">
<a href="./../../../../policies/index.html">Policies</a><ul class="sub-menu">
<li id="menu-item-3497" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-privacy-policy menu-item-3497"><a href="./../../../../services/privacy-policy/index.html">Privacy Statement</a></li>
<li id="menu-item-3739" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3739"><a href="./../../../../services/ordering-details-terms-and-conditions/index.html">Ordering Details, Terms, and Conditions</a></li>
<li id="menu-item-3738" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3738"><a href="./../../../../services/browser-recommendation/index.html">Browser Recommendation</a></li>
<li id="menu-item-3737" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3737"><a href="./../../../../services/new-product-suggestion/index.html">New Product Suggestion</a></li>
</ul>
</li>
<li id="menu-item-3594" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3594"><a href="./../../../../services/partner_with_us/index.html">Partner with us</a></li>
<li id="menu-item-3494" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3494"><a href="./../../../../careers/index.html">Careers</a></li>
<li id="menu-item-4734" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4734"><a href="./../../../../library/index.html">Library</a></li>
<li id="menu-item-3438" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3438"><a href="./../../../../contact/index.html">Contact</a></li>
</ul> </nav>
</div>
</div>
</div>
</header>


<!--page-content-here-->
<div class="btContentWrap btClear" style="padding-top: 201px;">
<section class="boldSection bottomSemiSpaced btPageHeadline gutter  topSemiSpaced btTextLeft " data-parallax="0.8" data-parallax-offset="0"><div class="port"><header class="header btClear large"><div class="btSuperTitle"><span><div class="btBreadCrumbs"><nav><ul><span class="btArticleCategories"><a href="./../../../..//category/articles/" class="btArticleCategory cat-item-52">Articles</a></span></ul></nav></div></span></div><div class="dash"><h2><span class="headline">Exemestane for Breast-Cancer Prevention in Postmenopausal Women</span></h2></div><div class="btSubTitle"><span class="btArticleDate">16.08.2021</span><a href="./../../../..//2021/08/16/exemestane-for-breast-cancer-prevention-in-postmenopausal-women/#comments" class="btArticleComments">0</a></div></header></div></section> <div class="btContentHolder">
<div class="btContent">
<article class="boldSection btArticle gutter divider noPhoto post-5256 post type-post status-publish format-standard hentry category-articles btPostSingleItemStandard"><div class="port"><div class="boldCell"><div class="boldRow"><div class="rowItem col-sm-12"><div class="btArticleBody portfolioBody btTextLeft"><div class="bt_bb_wrapper"><p>Paul E. Goss, M.D., Ph.D.,&nbsp;James N. Ingle, M.D.,&nbsp;José E. Alés-Martínez, M.D., Ph.D.,&nbsp;Angela M. Cheung, M.D., Ph.D.,&nbsp;Rowan T. Chlebowski, M.D., Ph.D.,&nbsp;Jean Wactawski-Wende, Ph.D.,&nbsp;Anne McTiernan, M.D.,&nbsp;John Robbins, M.D.,&nbsp;Karen C. Johnson, M.D., M.P.H.,&nbsp;Lisa W. Martin, M.D.,&nbsp;Eric Winquist, M.D.,&nbsp;Gloria E. Sarto, M.D.,</p>
<p>&nbsp;</p>
<h2 class="o-article-body__section-title a-article-h1 a-article-h1--underline f-h3">Abstract</h2>
<hr>
<p>&nbsp;</p>
<section id="article_Abstract" class="o-article-body__section" data-article-section-title="Abstract">
<h2 class="a-article-h2 f-h12">BACKGROUND</h2>
<p class="f-body">Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer.</p>
<h2 class="a-article-h2 f-h12">METHODS</h2>
<p class="f-body">In a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65% relative reduction in invasive breast cancer, eligible postmenopausal women 35 years of age or older had at least one of the following risk factors: 60 years of age or older; Gail 5-year risk score greater than 1.66% (chances in 100 of invasive breast cancer developing within 5 years); prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ; or ductal carcinoma in situ with mastectomy. Toxic effects and health-related and menopause-specific qualities of life were measured.</p>
<h2 class="a-article-h2 f-h12">RESULTS</h2>
<p class="f-body">A total of 4560 women for whom the median age was 62.5 years and the median Gail risk score was 2.3% were randomly assigned to either exemestane or placebo. At a median follow-up of 35 months, 11 invasive breast cancers were detected in those given exemestane and in 32 of those given placebo, with a 65% relative reduction in the annual incidence of invasive breast cancer (0.19% vs. 0.55%; hazard ratio, 0.35; 95% confidence interval [CI], 0.18 to 0.70; P=0.002). The annual incidence of invasive plus noninvasive (ductal carcinoma in situ) breast cancers was 0.35% on exemestane and 0.77% on placebo (hazard ratio, 0.47; 95% CI, 0.27 to 0.79; P=0.004). Adverse events occurred in 88% of the exemestane group and 85% of the placebo group (P=0.003), with no significant differences between the two groups in terms of skeletal fractures, cardiovascular events, other cancers, or treatment-related deaths. Minimal quality-of-life differences were observed.</p>
<h2 class="a-article-h2 f-h12">CONCLUSIONS</h2>
<p class="f-body">Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer. During a median follow-up period of 3 years, exemestane was associated with no serious toxic effects and only minimal changes in health-related quality of life. (Funded by Pfizer and others; NCIC CTG MAP.3 ClinicalTrials.gov number,&nbsp;<a class="ext-link" href="https://clinicaltrials.gov/show/NCT00083174" target="_blank" rel="noopener">NCT00083174<span class="sr-only">. opens in new tab</span></a>.)</p>
</section>
<section id="article_introduction" class="o-article-body__section o-article-body__section--collapsible o-article-body__section--collapsible-open@medium+ o-article-body__section--hide-title@medium+ section-in-viewport" data-behavior="CollapsibleArea" data-article-section-title="Introduction">
<div class="o-article-body__collapsible" data-collapsible-block="">
<div class="o-article-body__collapsible-content">
<p class="f-body f-body--w-dropcap">Estrogens contribute to normal breast development but can also promote breast cancer in preclinical models and in women with high circulating plasma estrogen levels.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref1,ref2,ref3,ref4">1-4</a></sup>&nbsp;To date, chemoprevention of breast cancer has focused on the selective estrogen-receptor modulators (SERMs) tamoxifen and raloxifene, which exert antiestrogenic effects on the breast, as well as agonist or antagonist effects on other organs. In the National Surgical Adjuvant Breast and Bowel Project P-1 trial, tamoxifen significantly reduced the number of invasive breast cancers, by 49% (P&lt;0.001) as compared with placebo.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref5">5</a></sup>&nbsp;A meta-analysis of trials comparing tamoxifen with placebo showed that tamoxifen reduced the incidence of breast cancer by 38% with no effect on mortality.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref6">6</a></sup>&nbsp;On the basis of these collective data on tamoxifen, the estimated number needed to treat to prevent one breast cancer after 5 years is about 95 and is reduced to 56 after 10 years.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref7">7</a></sup>&nbsp;Similar risk reductions occur with raloxifene.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref8,ref9,ref10">8-10</a></sup>&nbsp;Tamoxifen increases the risks of endometrial cancers and venous thromboembolism; raloxifene does not increase the risk of endometrial cancers but does cause similar toxic effects.</p>
<p class="f-body">The acceptance of tamoxifen or raloxifene for reducing the risk of breast cancer has been poor, in part because they are both associated with rare but serious toxic effects.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref11,ref12,ref13">11-13</a></sup>&nbsp;Of the approximately 2 million U.S. women who could potentially benefit from treatment with tamoxifen, only 4% of those at increased risk for breast cancer and only 0.08% of all U.S. women 40 to 79 years of age have accepted the use of this drug for chemoprevention.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref13,ref14,ref15">13-15</a></sup>&nbsp;A 2002 expert assessment concluded that tamoxifen lacks overall health benefits and recommended that future trials be conducted with placebo controls.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref16">16</a></sup>&nbsp;Novel, less toxic interventions are needed that will reduce the threshold of risk yet provide a net benefit.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref17">17</a></sup></p>
<div data-mboxid="nejm-article-inline" data-location="mbox" data-location-name="nejm-article-inline"></div>
<p class="f-body">Aromatase inhibitors profoundly suppress estrogen levels in postmenopausal women and inhibit the development of breast cancer in laboratory models.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref18,ref19,ref20,ref21">18-21</a></sup>&nbsp;In early trials of breast cancer therapy, both nonsteroidal and steroidal aromatase inhibitors reduced contralateral primary breast cancers more than did tamoxifen; after 5 years of tamoxifen therapy, letrozole resulted in a further reduction of 46%, as compared with placebo.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref22,ref23,ref24,ref25,ref26,ref27">22-27</a></sup>&nbsp;Preclinical models and clinical studies suggest that because of exemestane’s antiestrogenic effects, such as those on bone resorption due to this drug’s mild androgenic activity, it is a good candidate for study in a breast-cancer prevention trial.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref28,ref29,ref30">28-30</a></sup></p>
</div>
</div>
</section>
<p>&nbsp;</p>
<h2 class="o-article-body__section-title a-article-h1 a-article-h1--underline f-h3" tabindex="0" data-collapsible-trigger="" aria-title="Methods toggle">Methods</h2>
<hr>
<p>&nbsp;</p>
<h2 class="a-article-h2 f-h12" tabindex="0" data-collapsible-trigger="" aria-title="Study Design toggle">STUDY DESIGN</h2>
<p class="f-body">The NCIC Clinical Trials Group Mammary Prevention.3 trial (NCIC CTG MAP.3) is an international, randomized, double-blind, placebo-controlled trial conducted in Canada, the United States, Spain, and France. The trial was approved by the health regulatory authorities and institutional review boards at the participating centers, and enrollment began in September 2004. After stratification according to current use of low-dose aspirin (≤100 mg per day) (yes or no) and Gail risk score (for calculation of this score, see&nbsp;<a class="ext-link" href="http://www.cancer.gov/bcrisktool" target="_blank" rel="noopener">www.cancer.gov/bcrisktool<span class="sr-only">. opens in new tab</span></a>&nbsp;and the&nbsp;<a href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1103507/suppl_file/nejmoa1103507_appendix.pdf" data-interactiontype="multimedia_download" data-download-format="PDF" data-behavior="trackDownloadEvent" data-download-filetype="PDF" data-download-type="Supplementary Appendix">Supplementary Appendix</a>, available with the full text of this article at NEJM.org) (≤2.0% or &gt;2.0%), subjects were randomly assigned to one of three treatment groups with the use of a dynamic minimization algorithm: 25 mg of exemestane plus placebo, 25 mg of exemestane plus celecoxib, or placebo plus placebo pills, administered daily after a morning meal.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref31,ref32">31,32</a></sup>&nbsp;After 31 patients were enrolled, 10 patients discontinued treatment with celecoxib because of concern for cardiovascular safety.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref33">33</a></sup>&nbsp;Before enrollment and during the study, written informed consent and reconsent in all the participating countries included counseling about the risks and benefits of treatment with tamoxifen and raloxifene. The trial was event-driven, with a planned maximum duration of therapy of 5 years or until a breast event, a neoplastic disease, or a cardiovascular event was diagnosed or unacceptable toxicity developed.</p>
<h2 class="a-article-h2 f-h12" tabindex="0" data-collapsible-trigger="" aria-title="Participants toggle">PARTICIPANTS</h2>
<p class="f-body">Women 35 years of age or older were eligible if they were postmenopausal (older than 50 years of age with no spontaneous menses for at least 12 months; or 50 years of age or younger either with no spontaneous menses [amenorrheic] within 12 months of randomization [e.g., spontaneous or secondary to hysterectomy] and a follicle-stimulating hormone level within the postmenopausal range or with prior bilateral oophorectomy). In addition, women had at least one of the following risk factors: age 60 years or older; Gail risk score greater than 1.66%; prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ on breast biopsy or prior ductal carcinoma in situ treated with mastectomy. Prior menopausal hormone therapies (estrogen with or without progestin), luteinizing hormone–releasing hormone analogues, prolactin inhibitors, antiandrogens, or selective estrogen-receptor modulators were allowable, but not within 3 months of randomization. Women were ineligible if they were premenopausal, had prior invasive breast cancer or prior ductal carcinoma in situ treated with lumpectomy, were known carriers of the BRCA1 or BRCA2 gene, had a history of other malignancies (except nonmelanoma skin cancer, treated in situ cancer of the cervix, or other solid tumors treated with no evidence of disease for 5 years), had uncontrolled hypothyroidism or hyperthyroidism, or had chronic liver disease.</p>
<h2 class="a-article-h2 f-h12" tabindex="0" data-collapsible-trigger="" aria-title="End Points and Assessment toggle">END POINTS AND ASSESSMENT</h2>
<p class="f-body">The primary outcome was incidence of invasive breast cancer. Secondary end points included a combined incidence of invasive and noninvasive (ductal carcinoma in situ) breast cancer; incidence of receptor-negative invasive breast cancer; incidence of combined atypical ductal hyperplasia, atypical lobular hyperplasia, and lobular carcinoma in situ; number of clinical breast biopsies; clinical fractures; adverse cardiovascular events, including myocardial infarction or coronary heart disease that resulted in death; overall incidence of other cancers; the side-effect profile and safety; and health-related and menopause-specific qualities of life (assessed by means of the Medical Outcomes Study 36-Item Short-Form Health Survey [SF-36] and the Menopause-Specific Quality of Life [MENQOL] questionnaire, respectively<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref34,ref35,ref36">34-36</a></sup>).</p>
<p class="f-body">At baseline, each patient’s history of prior diseases and treatment, family history of cancer, and reproductive history were obtained. Physical examination was performed, including height, weight, blood pressure, pulse, and clinical breast examination to confirm no suspicious breast abnormalities. Other requirements included complete blood count, liver-function tests, renal-function tests, and normal results on bilateral mammography and bone-mineral-density measurements within the past year. Symptoms at baseline were graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref37">37</a></sup>&nbsp;Quality of life (QOL) was measured within 1 week before randomization. Clinical assessments occurred at 6 and 12 months after randomization and yearly thereafter and included physical examination with clinical breast examinations, recording of concomitant medications, symptoms and adverse events, and QOL assessments. Women discontinuing the study drug continued to undergo clinical assessments and follow-up for clinical outcomes and adverse events.</p>
<p class="f-body">Mammography was required within 12 months before randomization and every 12 months from the time of the initial mammogram during and after the treatment. Breast cancers could be detected on clinical breast examination during the clinic visits or on annual mammography. All mammograms and radiographic reports of fractures were reviewed centrally, and all evidence of disease on breast-biopsy specimens was reviewed by an adjudication committee. Study accrual and safety data were reviewed every 6 months by an independent data and safety monitoring committee. The original&nbsp;<a href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1103507/suppl_file/nejmoa1103507_protocol.pdf" data-interactiontype="multimedia_download" data-download-format="PDF" data-behavior="trackDownloadEvent" data-download-filetype="PDF" data-download-type="Supplementary Protocol">protocol</a>&nbsp;and subsequent amendments are available at NEJM.org.</p>
<h2 class="a-article-h2 f-h12" tabindex="0" data-collapsible-trigger="" aria-title="Statistical Analysis toggle">STATISTICAL ANALYSIS</h2>
<p class="f-body">The planned final analyses presented here include invasive breast cancer incidence and other secondary breast cancer end points, estimated on the basis of time from randomization to when an end point was reached. The sample-size estimate was based on an assumption of a rate of invasive breast cancer of 0.60% per year in the group given placebo, as compared with 0.21% in those treated with exemestane, with a relative reduction of 65% with exemestane. To detect this with a two-sided 5% level and 90% power, a total of 38 cases of invasive breast cancer were required, projected to occur when 4560 women were randomly assigned to treatment groups in a 3-year period and then followed for an additional 1.2 years. No interim analyses were planned. Accrual was completed on March 23, 2010; the protocol target-event rate was met on November 5, 2010. All data queries were resolved, and the database was locked on March 1, 2011.</p>
<p class="f-body">Comparisons of time-to-event primary and secondary end points were based on the stratified log-rank test, adjusting for the two stratification factors at randomization. Cox proportional-hazards models were used to derive hazard ratios and associated 95% confidence intervals. Fisher’s exact test was used to compare adverse events between the treatment and placebo groups. Mean change scores from baseline to each assessment were calculated for all SF-36 and MENQOL subscales and summaries. Changes measuring 5 to 10% of the scale breadth or 0.5 SD were considered to be potentially clinically meaningful.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref38,ref39,ref40">38-40</a></sup>&nbsp;Scores measuring changes in QOL were considered worsened if they decreased by 5 or more points (out of a total of 100) from baseline on the SF-36 and if they increased by 0.5 or more points (out of a total of 8) on the MENQOL. A chi-square test was used to compare the differences in proportions of patients found to have potentially clinically meaningful changes in QOL.</p>
<p class="f-body">The study drug, exemestane, and funding support were provided by Pfizer, but this sponsor had no role in the design of the study or in the accrual, management, or analysis of the data. The decision to publish and the drafting of the manuscript were undertaken entirely by the first author, coauthors, and staff at the NCIC CTG central office, who vouch for the fidelity of the study to the protocol and for the accuracy and completeness of the data.</p>
<p>&nbsp;</p>
<h2 class="o-article-body__section-title a-article-h1 a-article-h1--underline f-h3" tabindex="0" data-collapsible-trigger="" aria-title="Results toggle">Results</h2>
<hr>
<p>&nbsp;</p>
<p>Between February 11, 2004, and March 23, 2010, 4560 women were randomly assigned to either exemestane (2285 patients) or placebo (2275 patients). After randomization, 15 women (6 taking exemestane and 9 taking placebo) were considered to be ineligible to continue with the study but are included in the primary intention-to-treat analysis as randomly assigned. The exemestane and placebo groups were well balanced for race, body-mass index, and breast cancer risk factors (<span id="t01" class="holder"><a class="js__showFigure" title="View full size" href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-figure-id="t01" data-multimedia-type-ff="Table" data-multimedia-content="Table" data-multimedia-contentid-ff="10.1056/NEJMoa1103507-t01" data-rid="t01" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJMoa1103507-t01" data-fv-download-contentid="10.1056/NEJMoa1103507-t01" data-fv-interactiontype="multimedia_download" data-fv-download-type="Table">Table 1</a></span>, and Table 1 in the&nbsp;<a href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1103507/suppl_file/nejmoa1103507_appendix.pdf" data-interactiontype="multimedia_download" data-download-format="PDF" data-behavior="trackDownloadEvent" data-download-filetype="PDF" data-download-type="Supplementary Appendix">Supplementary Appendix</a>).</p>
<p><span class="f-caption f-h11" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJMoa1103507-t01">Table 1.&nbsp;</span><span class="f-caption f-caption--title" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJMoa1103507-t01">Baseline Characteristics of Patients Randomly Assigned to Exemestane or Placebo.</span></p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2011/nejm_2011.364.issue-25/nejmoa1103507/20161122/images/img_large/nejmoa1103507_t1.jpeg"><noscript>&lt;img src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2011/nejm_2011.364.issue-25/nejmoa1103507/20161122/images/img_large/nejmoa1103507_t1.jpeg" /&gt;</noscript></p>
<p>&nbsp;</p>
<p class="f-body fig-paragraph">Major risk factors among the women who were enrolled included age of at least 60 years (49%); 5-year risk of breast cancer developing (Gail risk score &gt;1.66%) (40%), and prior atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, or prior ductal carcinoma in situ treated with mastectomy (11%). Prior menopausal hormone therapy use was recorded in 1310 women in the exemestane group (57.3%; range from 1 to 588 months) and 1327 women in the placebo group (58.3%; range from 1 to 360 months). Pretreatment bone mineral density and prior history of clinical fractures, cardiovascular risk factors, and the concomitant use of bisphosphonates, lipid-lowering drugs, and cardiovascular drugs were similar in the two study groups.</p>
<p class="f-body">On November 5, 2010, at the time of the clinical data cutoff, 735 women (32.8%) assigned to exemestane and 646 women (28.7%) assigned to placebo were no longer taking the study medication. About 5% in each group had discontinued the protocol treatment because of treatment completion. The major reasons for early discontinuation of the protocol treatments were toxic effects (15.4% in the exemestane groups vs. 10.8% in the placebo group, P&lt;0.001) and patient refusal (6.9% vs. 6.0%, P=0.22). The median time from randomization to off-protocol treatment was 10.2 months (range, 0.1 to 61.5) for exemestane and 14.2 months (range, 0.1 to 62.9) for placebo. Approximately 85% of women were compliant and 15% were noncompliant with the protocol guidelines for the study treatments. Scheduled annual mammography was performed equally in the two groups, with 7.2% and 7.7% of women having missed at least one scheduled mammography appointment in the exemestane and placebo groups, respectively.</p>
<p>&nbsp;</p>
<p>At a median of 35 months of follow-up (range, 0 to 63.4), 43 invasive breast cancers were diagnosed: 11 in the exemestane groups and 32 in the placebo group (annual incidence, 0.19% with exemestane vs. 0.55% with placebo; hazard ratio, 0.35 with exemestane; 95% confidence interval [CI], 0.18 to 0.70) (<span id="t02" class="holder"><a class="js__showFigure" title="View full size" href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-figure-id="t02" data-multimedia-type-ff="Table" data-multimedia-content="Table" data-multimedia-contentid-ff="10.1056/NEJMoa1103507-t02" data-rid="t02" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJMoa1103507-t02" data-fv-download-contentid="10.1056/NEJMoa1103507-t02" data-fv-interactiontype="multimedia_download" data-fv-download-type="Table">Table 2</a></span>).&nbsp;<span id="f01" class="holder"><a class="js__showFigure" title="View full size" href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-figure-id="f01" data-multimedia-type-ff="Image" data-multimedia-content="Figure" data-multimedia-contentid-ff="10.1056/NEJMoa1103507-f01" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-format="Image" data-multimedia-contentid="10.1056/NEJMoa1103507-f01" data-fv-download-contentid="10.1056/NEJMoa1103507-f01" data-fv-interactiontype="multimedia_download" data-fv-download-type="Figure">Figure 1</a></span>&nbsp;shows the cumulative incidence of invasive breast cancer in these two groups. There were 37 ductal (10 in the exemestane groups and 27 in the placebo group) and 6 lobular (1 in the exemestane groups and 5 in the placebo group) cancers. The majority of cancers in each group were estrogen-receptor–positive, HER2/neu–negative, and node-negative (<span id="t02" class="holder"><a class="js__showFigure" title="View full size" href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-figure-id="t02" data-multimedia-type-ff="Table" data-multimedia-content="Table" data-multimedia-contentid-ff="10.1056/NEJMoa1103507-t02" data-rid="t02" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJMoa1103507-t02" data-fv-download-contentid="10.1056/NEJMoa1103507-t02" data-fv-interactiontype="multimedia_download" data-fv-download-type="Table">Table 2</a></span>).</p>
<p><span class="f-caption f-h11" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJMoa1103507-t02">Table 2.&nbsp;</span><span class="f-caption f-caption--title" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJMoa1103507-t02">Incidence of Invasive and Preinvasive Breast Events by Treatment Group.</span></p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2011/nejm_2011.364.issue-25/nejmoa1103507/20161122/images/img_xlarge/nejmoa1103507_t2.jpeg"><noscript>&lt;img src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2011/nejm_2011.364.issue-25/nejmoa1103507/20161122/images/img_xlarge/nejmoa1103507_t2.jpeg" /&gt;</noscript></p>
<p><span class="f-caption f-h11" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-format="Image" data-multimedia-contentid="10.1056/NEJMoa1103507-f01">Figure 1.&nbsp;</span><span class="f-caption f-caption--title" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-format="Image" data-multimedia-contentid="10.1056/NEJMoa1103507-f01">Cumulative Incidence of Invasive Breast Cancer.</span></p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2011/nejm_2011.364.issue-25/nejmoa1103507/20161122/images/img_xlarge/nejmoa1103507_f1.jpeg"><noscript>&lt;img src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2011/nejm_2011.364.issue-25/nejmoa1103507/20161122/images/img_xlarge/nejmoa1103507_f1.jpeg" /&gt;</noscript></p>
<p>&nbsp;</p>
<p>Exemestane appeared to be superior to placebo in all prespecified subgroups defined by concurrent use of low-dose aspirin, Gail risk score, age, body-mass index, prior atypical ductal hyperplasia, atypical lobular hyperplasia, or lobular carcinoma in situ and prior ductal carcinoma in situ treated with mastectomy (<span id="f02" class="holder"><a class="js__showFigure" title="View full size" href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-figure-id="f02" data-multimedia-type-ff="Image" data-multimedia-content="Figure" data-multimedia-contentid-ff="10.1056/NEJMoa1103507-f02" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-format="Image" data-multimedia-contentid="10.1056/NEJMoa1103507-f02" data-fv-download-contentid="10.1056/NEJMoa1103507-f02" data-fv-interactiontype="multimedia_download" data-fv-download-type="Figure">Figure 2</a></span>). Exemestane also appeared to be superior in unplanned subgroups: invasive breast cancers according to prior use of menopausal hormone therapy (hazard ratio, 0.30 for prior users; 95% CI, 0.11 to 0.81; hazard ratio, 0.41 for prior nonusers; 95% CI, 0.16 to 1.05) and continent of residence (hazard ratio, 0.34 for North America; 95% CI, 0.16 to 0.71; hazard ratio, 0.39 for Europe; 95% CI, 0.07 to 1.99). The annual incidence of invasive breast cancer plus ductal carcinoma in situ (20 in the exemestane group and 44 in the placebo group) was 0.35% and 0.77% in the exemestane and placebo groups, respectively (hazard ratio, 0.47; 95% CI, 0.27 to 0.79). Combined lobular carcinoma in situ, atypical ductal hyperplasia, and atypical lobular hyperplasia occurred in 4 women (0.2%) in the exemestane group and 11 (0.5%) in the placebo group (hazard ratio, 0.36; 95% CI, 0.11 to 1.12). The number needed to treat to prevent one case of invasive breast cancer with exemestane therapy was 94 in 3 years and 26 in 5 years, but few women completed 5 years of therapy.</p>
<p>&nbsp;</p>
<p><span class="f-caption f-h11" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJMoa1103507-t03">Table 3.&nbsp;</span><span class="f-caption f-caption--title" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJMoa1103507-t03">Side Effects during Treatment, According to Severity.</span></p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2011/nejm_2011.364.issue-25/nejmoa1103507/20161122/images/img_xlarge/nejmoa1103507_t3.jpeg"><noscript>&lt;img src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2011/nejm_2011.364.issue-25/nejmoa1103507/20161122/images/img_xlarge/nejmoa1103507_t3.jpeg" /&gt;</noscript></p>
<p><span id="t03" class="holder"><a class="js__showFigure" title="View full size" href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-figure-id="t03" data-multimedia-type-ff="Table" data-multimedia-content="Table" data-multimedia-contentid-ff="10.1056/NEJMoa1103507-t03" data-rid="t03" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJMoa1103507-t03" data-fv-download-contentid="10.1056/NEJMoa1103507-t03" data-fv-interactiontype="multimedia_download" data-fv-download-type="Table">Table 3</a></span>&nbsp;(and Table 2 in the&nbsp;<a href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1103507/suppl_file/nejmoa1103507_appendix.pdf" data-interactiontype="multimedia_download" data-download-format="PDF" data-behavior="trackDownloadEvent" data-download-filetype="PDF" data-download-type="Supplementary Appendix">Supplementary Appendix</a>) shows adverse events that occurred in 5% or more of women, with a difference between groups of 1% or more and prespecified secondary end points of toxicity. Symptoms and adverse events (all grades) occurred in 88% of women in the exemestane group versus 85% in the placebo group (P=0.003). Arthritis (P=0.01) and hot flashes (P&lt;0.001) were more common in the exemestane group, but differences between the groups in the frequency of those with grade 2 or higher symptoms were modest (arthritis, 6.5% vs. 4.0%; hot flashes, 18.3% vs. 11.9%).&nbsp;<span id="t03" class="holder"><a class="js__showFigure" title="View full size" href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-figure-id="t03" data-multimedia-type-ff="Table" data-multimedia-content="Table" data-multimedia-contentid-ff="10.1056/NEJMoa1103507-t03" data-rid="t03" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJMoa1103507-t03" data-fv-download-contentid="10.1056/NEJMoa1103507-t03" data-fv-interactiontype="multimedia_download" data-fv-download-type="Table">Table 3</a></span>&nbsp;(and Table 2 in the&nbsp;<a href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1103507/suppl_file/nejmoa1103507_appendix.pdf" data-interactiontype="multimedia_download" data-download-format="PDF" data-behavior="trackDownloadEvent" data-download-filetype="PDF" data-download-type="Supplementary Appendix">Supplementary Appendix</a>) shows no significant differences between the two groups in prespecified secondary end points, including new diagnoses of osteoporosis or cardiovascular events. Clinical fracture rates were also similar in the two groups, and the proportion of women in each group who were prescribed bisphosphonate therapy during the trial was also similar (24.5% for exemestane and 24.1% for placebo). There was no significant difference in the number of cancers other than breast cancer (50 [2.2%] vs. 44 [2.0%]) or time to detection of these cancers (1.8 yr vs. 1.6 yr). No significant differences were detected between the two groups with respect to hypercholesterolemia, hypertriglyceridemia, abnormal liver-function tests, acne, alopecia, rash, weight gain, or hair loss (data not shown). Table 3 in the&nbsp;<a href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1103507/suppl_file/nejmoa1103507_appendix.pdf" data-interactiontype="multimedia_download" data-download-format="PDF" data-behavior="trackDownloadEvent" data-download-filetype="PDF" data-download-type="Supplementary Appendix">Supplementary Appendix</a>&nbsp;shows health-related and menopause-specific QOL results. Compliance in completing the QOL questionnaire at each follow-up visit was 92.9 to 97.4% for the exemestane group and 94.3 to 97.5% for the placebo group. No between-group differences in overall health-related QOL responses were found when distributions of worsened, stable, and improved scores on the SF-36 (Physical and Mental Component Scores) were compared despite worsened menopause-specific QOL among those taking exemestane (7% more overall). There were 38 deaths during the study (19 in each group). Causes of death in the exemestane and placebo groups, respectively, were breast cancer, 1 and 0; other malignancies, 10 and 12; cardiovascular events, 5 and 4; and other causes, 3 and 3. None were adjudicated as treatment-related.</p>
<p>&nbsp;</p>
<h2 class="o-article-body__section-title a-article-h1 a-article-h1--underline f-h3" tabindex="0" data-collapsible-trigger="" aria-title="Discussion toggle">Discussion</h2>
<hr>
<p>&nbsp;</p>
<section id="article_discussion_s011" class="o-article-body__section o-article-body__section--collapsible o-article-body__section--collapsible-open@medium+ section-in-viewport" data-behavior="CollapsibleArea" data-article-section-title="Discussion">
<div class="o-article-body__collapsible" data-collapsible-block="">
<div class="o-article-body__collapsible-content">
<p class="f-body">In this randomized, placebo-controlled trial in healthy postmenopausal women, exemestane reduced the relative incidence of invasive breast cancers by 65%, from 0.55% to 0.19%. Exemestane also reduced the risk of known breast-cancer precursor lesions — ductal carcinoma in situ, lobular carcinoma in situ, atypical ductal hyperplasia, and atypical lobular hyperplasia — suggesting possible further reductions in invasive cancers during long-term follow-up. Most tumors in these study patients were estrogen-receptor–positive. HER2-positive tumors, which have a poor prognosis, were also reduced with exemestane. Future studies to corroborate this finding would be important.</p>
<p class="f-body">Menopausal symptoms such as hot flashes, fatigue, sweating, insomnia, and arthralgia were frequent among all the women in the study but were predictably somewhat more common in those taking exemestane. Also of potential clinical importance, more women in the exemestane group self-reported that menopause-related vasomotor and sexual symptoms had worsened. However, these symptoms did not appear to affect self-reports of overall health-related QOL among those taking exemestane because summary measures of physical and mental components of the SF-36 did not differ between the two study groups. (Full QOL results are not reported here.) Unlike the rare endometrial cancers and thromboemboli associated with tamoxifen, particularly in postmenopausal women, no serious adverse events or end-organ toxic effects, including fractures, were attributable to exemestane. Mild loss of bone mineral density with the aromatase inhibitors is well documented, but the annual excess incidence of fractures in trials comparing aromatase inhibitors and tamoxifen are probably due mainly to the bone-protective effects of tamoxifen.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref41,ref42">41,42</a></sup>&nbsp;After the cessation of therapy in several large trials comparing aromatase inhibitors and tamoxifen in early breast cancer, bone mineral density improved and the difference in fracture rates was reduced.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref43,ref44,ref45">43-45</a></sup>&nbsp;In these trials, adverse events also attenuated rapidly after cessation of treatment and correlated with recovery of estrogen levels to their normal postmenopausal range. The absence of excess clinical fractures in patients treated with exemestane in this study is reassuring. This occurred despite similar baseline bone mineral density in the two groups and the use of bisphosphonate therapy both before and during the study. Although differences in the occurrence of colorectal, lung, and endometrial cancers and malignant melanomas have been reported in tamoxifen comparator trials, no differences were seen in this trial or in the placebo-controlled MA.17 trial.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref26,ref46">26,46</a></sup>&nbsp;Small numerical, but not significant, differences in the number of cardiovascular events have also been reported in trials comparing aromatase inhibitors with tamoxifen,<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref22,ref23,ref46">22,23,46</a></sup>&nbsp;with more events among the patients treated with aromatase inhibitors, and these differences may have been due to the slightly protective effect of tamoxifen, as suggested by Mouridsen et al.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref47">47</a></sup>&nbsp;It is reassuring that when the aromatase inhibitors were compared with placebo, these differences were not seen either in this prevention trial or in our early breast cancer MA.17 trial.</p>
<p class="f-body">This trial has some limitations. The median follow-up of 3 years is relatively short, and although consistent with our projections, the total number of breast events (66) was small. The optimal duration of endocrine therapy for breast-cancer prevention is not known, but in a previous placebo-controlled trial of early breast cancer, we found that prolonged aromatase-inhibitor therapy was associated with continued reductions in the incidence of contralateral breast cancers even after the aromatase inhibitor was discontinued.<sup><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1103507#" data-behavior="ShowPopupTip" data-popup-content-ids="ref48">48</a></sup>&nbsp;The number of women needed to treat in MAP.3 to prevent one case of breast cancer is 94 with 3 years of exemestane therapy, but is projected to be 26 at 5 years, although the number of women who received treatment for a full 5 years was low. By identifying subgroups of participants in the MAP.3 trial who would benefit most or who would be most vulnerable to toxic effects, one might be able to reduce the number needed to treat.</p>
<p class="f-body">Despite these limitations we found a favorable risk-to-benefit ratio with a strong preventive effect of exemestane and, with a limited median follow-up of 3 years, an excellent safety profile across a spectrum of women at average to high risk for breast cancer. We reached our protocol-specified number of events for this final analysis; after unblinding, women taking the active drug will be offered exemestane to complete 5 years of therapy, and MAP.3 sites will have the option of offering 5 years of exemestane treatment to those initially assigned to placebo. We and others are conducting placebo-controlled trials in healthy women and patients with early breast cancer to evaluate prolonged aromatase-inhibitor therapy in postmenopausal women of similar age. The results of these ongoing trials should contribute to our understanding of the long-term efficacy and toxicity of aromatase inhibitors.</p>
</div>
</div>
</section>
<section id="disclosures" class="o-article-body__section o-article-body__section--collapsible o-article-body__section--collapsible-open@medium+ o-article-body__section--hide-title@medium+" data-behavior="CollapsibleArea" data-article-section-title="Funding and Disclosures">
<div class="o-article-body__collapsible" data-collapsible-block="">
<div class="o-article-body__collapsible-content">
<div id="">
<p class="f-body--sm">Supported by the Canadian Cancer Society Research Institute, the Canadian Institutes for Health Research, Pfizer, and the Avon Foundation.</p>
</div>
<div id="">
<p class="f-body--sm"><a href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1103507/suppl_file/nejmoa1103507_disclosures.pdf" data-interactiontype="multimedia_download" data-download-format="PDF" data-behavior="trackDownloadEvent" data-download-filetype="PDF" data-download-type="Supplementary Disclosure Forms">Disclosure forms</a>&nbsp;provided by the authors are available with the full text of this article at NEJM.org.</p>
</div>
<p class="f-body--sm">This article (10.1056/NEJMoa1103507) was published on June 4, 2011, and updated on June 23, 2011, at NEJM.org.</p>
<p class="f-body--sm">We thank the 4560 women (2824 from the United States, 1285 from Canada, 432 from Spain, and 19 from France) who agreed to participate in this study; the trial committee; the many investigators, pharmacists, and clinical research associates involved in the trial; Drs. Joe Pater and Lois Shepherd, Dianne Johnston, and Andrea Hiltz for their enthusiastic and unwavering support; the members of the NCIC CTG Data Safety Monitoring Committee; the Central Office staff of the NCIC CTG who contributed to the conduct of the trial; and Pfizer Pharmaceuticals for support and for providing exemestane and placebo.</p>
</div>
</div>
</section>
<h2 class="o-article-body__section-title a-article-h1 a-article-h1--underline f-h3" data-collapsible-trigger="" aria-title="Affiliations toggle">Author Affiliations</h2>
<hr>
<p>&nbsp;</p>
<div id="">
<p class="f-body--sm">From Massachusetts General Hospital Cancer Center (P.E.G.) and Dana–Farber Cancer Institute (J.E.G.) — both in Boston; Mayo Clinic, Rochester, MN (J.N.I.); Hospital Nuestra Señora De Sonsoles, Ávila, Spain (J.E.A., on behalf of the Spanish Group for Breast Cancer Research); Los Angeles Biomedical Research Institute, Harbor–UCLA Medical Center, Torrance, CA (R.T.C.); University at Buffalo, Buffalo, NY (J.W.-W.); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle (A.M.); University of California, Davis, Sacramento (J.R.); University of Tennessee Health Science Center, Memphis (K.C.J.); George Washington University School of Medicine, Washington, DC (L.W.M.); University of Wisconsin School of Medicine and Public Health, Madison (G.E.S.); Kansas University Medical Center, Kansas City (C.J.F.); Centre Hospitalier Universitaire Arnaud de Villeneuve, Montpellier, France (P.P., on behalf of the National Federation of French Cancer Centers); University Health Network, Toronto (A.M.C.), London Health Sciences Centre, London, ON (E.W.), Unité de recherche en santé des populations de l’Université Laval, Quebec (E.M.), Queen’s University Pathology and Molecular Medicine, Kingston, ON (P.F.), British Columbia Cancer Agency, Vancouver, BC (K.A.G.), and NCIC Clinical Trials Group, Kingston, ON (D.T., H.R.) — all in Canada.</p>
</div>
<p class="f-body--sm">Address reprint requests to Dr. Goss at Massachusetts General Hospital Cancer Center, Lawrence House, LRH-302, Boston, MA 02114, or at&nbsp;<a class="email" href="mailto:pgoss@partners.org">pgoss@partners.org</a>.</p>
<div id="FN1">
<p class="f-body--sm">The NCIC Clinical Trials Group MAP.3 (NCIC CTG MAP.3) investigators are listed in the&nbsp;<a href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1103507/suppl_file/nejmoa1103507_appendix.pdf" data-interactiontype="multimedia_download" data-download-format="PDF" data-behavior="trackDownloadEvent" data-download-filetype="PDF" data-download-type="Supplementary Appendix">Supplementary Appendix</a>, available at NEJM.org.</p>
</div>
<p>&nbsp;</p>
<h2 class="o-article-body__section-title a-article-h1 a-article-h1--underline f-h3" tabindex="0" data-collapsible-trigger="" aria-title="References toggle" data-interactiontype="article_tab" data-tabname="referencesJump" aria-expanded="true">References</h2>
<hr>
<p>&nbsp;</p>
<p>1. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-285[Erratum, N Engl J Med 2001;344:1804.]<br>
2.Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:2029-2035<br>
3.Ahlgren M, Melbye M, Wohlfahrt J, Sorensen TIA. Growth patterns and the risk of breast cancer in women. N Engl J Med 2004;351:1619-1626<br>
4.The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616<br>
5.Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388<br>
6.Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300<br>
7.Cuzick J. Long-term follow-up in cancer prevention trials (It ain’t over till it’s over). Cancer Prev Res (Phila) 2010;3:689-691<br>
8.Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137<br>
9.Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-1761<br>
10.Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741<br>
11.Armstrong K, Quistberg DA, Micco E, Domchek S, Guerra C. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med 2006;166:2260-2265<br>
12.Lippman SM. The dilemma and promise of cancer chemoprevention. Nat Clin Pract Oncol 2006;3:523-523<br>
13.Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 2010;28:3090-3095<br>
14.Visvanathan K, Chlebowski RT, Hurley P, et al. American Society of Clinical Oncology 2008 clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235-3258<br>
15.Waters WA, Cronin KA, Graubard BI, Han PK, Freedman AN. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 2010;19:443-446<br>
16.Chlebowski RT, Col N, Winer EP, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002;20:3328-3343<br>
17.Gail MH. Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med 2011;30:1090-1104<br>
18.Goss PE. Breast cancer prevention — clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol 2003;86:487-493<br>
19.Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 1994;15:2775-2780<br>
20.De Coster R, Van Ginckel RF, Callens MJ, Goeminne NK, Janssens BL. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors. Cancer Res 1992;52:1240-1244<br>
21.Schieweck K, Bhatnagar AS, Batzl C, Lang M. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol 1993;44:633-636<br>
22.Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-1810<br>
23.The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.N Engl J Med 2005;353:2747-57. [Erratum, N Engl J Med 2006;354:2200.]<br>
24.Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092[Erratum, 2004;351:2461, 2006;355:1746.]<br>
25.van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomized phase 3 trial. Lancet 2011;377:321-331<br>
26.Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802<br>
27.Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-518<br>
28.Goss PE, Qi S, Josse RG, et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004;34:384-392<br>
29.Joahannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997;3:1101-1108<br>
30.Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 2007;9:R52-R52<br>
31.Tu D. Minimization Procedure. In: Chow SC, ed. Encyclopedia of biopharmaceutical statistics. 3rd ed. New York: Marcel Dekker, 2010:795-8.<br>
32.Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886<br>
33.Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080<br>
34.Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976;25:3130-3139<br>
35.Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-175[Erratum, Maturitas 1996;25:231.]<br>
36.Ware JE, Kosinksi M, Dewey JE. How to score version 2 of the SF-36 health survey. Lincoln, RI: QualityMetric, 2000.<br>
37.Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0. March 31, 2003.<br>
38.Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-592<br>
39.Wyrwich KW, Fihn SD, Tierney WM, Kroenke K, Babu AN, Wolinsky FD. Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report. J Gen Intern Med 2003;18:196-202<br>
40.Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931-6940<br>
41.Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629-3635<br>
42.Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:1051-1057<br>
43.Coleman RE, Banks LM, Girgis SI, et al. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat 2010;124:153-161<br>
44.Geisler J, Lonning PE, krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 2006;42:2968-2975<br>
45.Eastell R, Adams J, Clack G, et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol 2011;22:857-862<br>
46.Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010;11:1135-1141<br>
47.Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 2007;25:5715-5722<br>
48.Ingle JN, Tu D, Pater JL, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006;99:295-300</p>
<p>&nbsp;</p>
<h2>Source:</h2>
<p>https://www.nejm.org/doi/full/10.1056/nejmoa1103507</p>
</div></div></div></div><div class="boldRow topSmallSpaced bottomSmallSpaced"><div class="rowItem col-sm-6 tagsRowItem  btTextLeft"></div><div class="rowItem col-sm-6 cellRight shareRowItem  btTextRight"><div class="socialRow"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https:./../../../..//2021/08/16/exemestane-for-breast-cancer-prevention-in-postmenopausal-women/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div></div></div></article><section class="boldSection gutter bottomSemiSpaced"><div class="port"><div class="boldRow"><div class="rowItem col-sm-12 btTextLeft"><div class="btClear btSeparator bottomSmallSpaced border"><hr></div>
 </div></div><div class="boldRow"><div class="rowItem col-sm-12"><div class="btClear btSeparator bottomMediumSpaced border"><hr></div></div></div><div class="boldRow btNextPrevRow neighboringArticles bottomSmallSpaced"><div class="rowItem col-sm-12 col-md-6 btTextLeft"><h4 class="nbs nsPrev"><a href="./../../../..//2021/08/03/safety-and-efficacy-of-oxandrolone-in-growth-hormone-treated-girls-with-turner-syndrome-evidence-from-recent-studies-and-recommendations-for-use/"><span class="nbsImage"><span class="nbsImgHolder"></span></span><span class="nbsItem"><span class="nbsDir">previous</span><span class="nbsTitle">Safety and Efficacy of Oxandrolone in Growth Hormone-Treated Girls with Turner Syndrome: Evidence from Recent Studies and Recommendations for Use</span></span></a></h4></div><div class="rowItem col-sm-12 col-md-6 btTextRight"></div></div></div></section>
</div>
</div>
</div>

<div class="bt_bb_wrapper"><section id="bt_section610e3a31c4f1c" data-parallax="0.7" data-parallax-offset="0" class="boldSection btDivider topSpaced bottomSemiSpaced btDarkSkin gutter boxed inherit btParallax" style="background-color:#1a86d3  !important;"><div class="port"><div class="boldCell"><div class="boldCellInner"><div class="boldRow "><div class="boldRowInner">
<div class="rowItem col-md-3 col-sm-6 col-ms-12 btTextLeft" data-width="3"><div class="rowItemContent">
<header class="header btClear small btDash bottomDash  regular"><div class="btSuperTitle"><span>HONG KONG</span></div>
<div class="dash"><h4><span class="headline">Headquarter</span></h4></div></header><span class="btIco btIcoDefaultType btIcoSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../index.html" target="no_target" data-ico-es="&#xe964;" class="btIcoHolder"><span>+852 3575 9046 </span></a></span><div class="btClear btSeparator noBorder"><hr></div>
<span class="btIco btIcoDefaultType btIcoSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../index.html" target="_self" data-ico-fa="&#xf0c1;" class="btIcoHolder"><span>www.ikigaicorporation.com</span></a></span><div class="btClear btSeparator noBorder"><hr></div>
<div class="bpgPhoto btDefaultHoverType">
<a href="./../../../../index.html" target="_self" title=""></a>
<div class="boldPhotoBox"><div class="bpbItem"><div class="btImage">
<img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="" title="" data-lazy-src="./../../../../wp-content/uploads/2020/05/HK-e1588760431256.png"><noscript><img src="./../../../../wp-content/uploads/2020/05/HK-e1588760431256.png" alt="" title=""></noscript>
</div></div></div>
<div class="captionPane btDarkSkin btTextCenter">
<div class="captionTable">
<div class="captionCell">
<div class="captionTxt"></div>
</div>
</div>
</div>
</div>
</div></div>
<div class="rowItem col-md-6 col-sm-12 btTextLeft" data-width="6"><div class="rowItemContent">
<header class="header btClear small btDash bottomDash  regular"><div class="btSuperTitle"><span>LOCATIONS</span></div>
<div class="dash"><h4><span class="headline">Our network</span></h4></div></header><div class="btClear btSeparator bottomSmallSpaced noBorder"><hr></div>
<div class="boldRow "><div class="boldRowInner">
<div class="rowItem rowInnerItem col-sm-6  btTextLeft"><div class="rowItemContent">
<div class="bpgPhoto btDefaultHoverType"><div class="btImage">
<img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="" title="						" data-lazy-src="./../../../../wp-content/uploads/2016/10/world-dot-map-gray-320x156.png"><noscript><img src="./../../../../wp-content/uploads/2016/10/world-dot-map-gray-320x156.png" alt="" title="						"></noscript>
</div></div>
<div class="btClear btSeparator topSmallSpaced noBorder"><hr></div>
</div></div>
<div class="rowItem rowInnerItem col-sm-6  btTextLeft"><div class="rowItemContent">
<header class="header btClear small  "><div class="btSuperTitle"><span>OUR NETWORK</span></div></header><div class="btClear btSeparator bottomExtraSmallSpaced noBorder"><hr></div>
<span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Asia</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Americas</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Middle East</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Europe</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Africa</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Oceania</span></a></span>
</div></div>
</div></div>
<div class="btClear btSeparator bottomExtraSmallSpaced noBorder"><hr></div>
<div class="btClear btSeparator bottomSemiSpaced noBorder"><hr></div>
</div></div>
<div class="rowItem col-md-3 col-sm-6 col-ms-12 btTextLeft" data-width="3"><div class="rowItemContent">
<header class="header btClear small btDash bottomDash  regular"><div class="btSuperTitle"><span>GET IN TOUCH</span></div>
<div class="dash"><h4><span class="headline">Follow us</span></h4></div></header><div class="btClear btSeparator bottomSmallSpaced noBorder"><hr></div>
<span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://www.facebook.com/ikigaicorporationcom" target="no_target" data-ico-fa="&#xf09a;" class="btIcoHolder"></a></span><span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://www.instagram.com/ikigaicorporation" target="no_target" data-ico-fa="&#xf16d;" class="btIcoHolder"></a></span><span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://www.google.com/maps/place/IKIGAI+CORPORATION+LTD/@22.3937048,113.9694348,17z/data=!3m1!4b1!4m5!3m4!1s0x3403fb18add189e3:0xccf4eec041856f0d!8m2!3d22.3936999!4d113.9716288" target="no_target" data-ico-fa="&#xf1a0;" class="btIcoHolder"></a></span><span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://wa.me/message/UZHAWI3JZQDVB1" target="no_target" data-ico-fa="&#xf232;" class="btIcoHolder"></a></span><div class="btClear btSeparator bottomSemiSpaced noBorder"><hr></div>
</div></div>
</div></div></div></div></div></section></div>
<footer>
  <section class="boldSection gutter btSiteFooter btGutter">
<div class="port">
<div class="boldRow">
<div class="rowItem btFooterCopy col-md-6 col-sm-12 btTextLeft">
<p class="copyLine">Ikigai Corporation Company is a leading pharmaceutical contract development and manufacturing organisation (CDMO) for both APIs and finished dose forms.</p> </div>
<div class="rowItem btFooterMenu col-md-6 col-sm-12 btTextRight">
<ul id="menu-primary-menu-1" class="menu">
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-3253"><a title="						" href="./../index.html">Home</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3403"><a href="./../about-us/index.html">About us</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-3451 current_page_item menu-item-3459"><a href="./index.html" aria-current="page">Our Technology</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3256"><a title="						" href="./../services/index.html">Product Portfolio</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3872"><a href="./../policies/index.html">Policies</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3594"><a href="./../services/partner_with_us/index.html">Partner with us</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3494"><a href="./../careers/index.html">Careers</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4734"><a href="./../library/index.html">Library</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3438"><a href="./../contact/index.html">Contact</a></li>
</ul> </div>
</div>
</div>
</section>
</footer>
</div>
<script >window.addEventListener('DOMContentLoaded', function() {
				(function( $ ) {
					$( document ).ready(function() {
						
						var time_notation = '24';
						
						var time = function() {
							
							if ( time_notation == '12' ) {
								var time = moment().tz( 'Asia/Hong_Kong' ).format( 'h:mm A' );
							} else {
								var time = moment().tz( 'Asia/Hong_Kong' ).format( 'H:mm' );
							}

							$( '#time610e3a31c10e7 .btIconWidgetText' ).html( time );
						}
						setInterval( function() {
							time();
						}, 1000 );
						time();
					});
				})( jQuery );
			});</script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-includes/js/comment-reply.min.js?ver=5.8" id="comment-reply-js" defer></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" id="buttonizer_frontend_javascript-js-extra">
/* <![CDATA[ */
var buttonizer_ajax = {"ajaxurl":".\/wp-admin\/admin-ajax.php","version":"2.4.3","buttonizer_path":".\/wp-content\/plugins\/buttonizer-multifunctional-button","buttonizer_assets":".\/wp-content\/plugins\/buttonizer-multifunctional-button\/assets\/","base_url":".","current":[],"in_preview":"","is_admin":"","cache":"ec7e88ea4f3f1891d22d4075828b5b63","enable_ga_clicks":"1"};
/* ]]> */
</script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/buttonizer-multifunctional-button/assets/frontend.min.js?v=7ab4fd8a7cd8bd136942183145de39a0&#038;ver=5.8" id="buttonizer_frontend_javascript-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/modal-for-elementor/js/bootstrap.js?ver=1620657753" id="bootstrap-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/modal-for-elementor/js/popup.js?ver=1620657753" id="modal-popup-js-js" defer></script>
<script  data-rocket-type="text/javascript" id="rocket-browser-checker-js-after">
"use strict";var _createClass=function(){function defineProperties(target,props){for(var i=0;i<props.length;i++){var descriptor=props[i];descriptor.enumerable=descriptor.enumerable||!1,descriptor.configurable=!0,"value"in descriptor&&(descriptor.writable=!0),Object.defineProperty(target,descriptor.key,descriptor)}}return function(Constructor,protoProps,staticProps){return protoProps&&defineProperties(Constructor.prototype,protoProps),staticProps&&defineProperties(Constructor,staticProps),Constructor}}();function _classCallCheck(instance,Constructor){if(!(instance instanceof Constructor))throw new TypeError("Cannot call a class as a function")}var RocketBrowserCompatibilityChecker=function(){function RocketBrowserCompatibilityChecker(options){_classCallCheck(this,RocketBrowserCompatibilityChecker),this.passiveSupported=!1,this._checkPassiveOption(this),this.options=!!this.passiveSupported&&options}return _createClass(RocketBrowserCompatibilityChecker,[{key:"_checkPassiveOption",value:function(self){try{var options={get passive(){return!(self.passiveSupported=!0)}};window.addEventListener("test",null,options),window.removeEventListener("test",null,options)}catch(err){self.passiveSupported=!1}}},{key:"initRequestIdleCallback",value:function(){!1 in window&&(window.requestIdleCallback=function(cb){var start=Date.now();return setTimeout(function(){cb({didTimeout:!1,timeRemaining:function(){return Math.max(0,50-(Date.now()-start))}})},1)}),!1 in window&&(window.cancelIdleCallback=function(id){return clearTimeout(id)})}},{key:"isDataSaverModeOn",value:function(){return"connection"in navigator&&!0===navigator.connection.saveData}},{key:"supportsLinkPrefetch",value:function(){var elem=document.createElement("link");return elem.relList&&elem.relList.supports&&elem.relList.supports("prefetch")&&window.IntersectionObserver&&"isIntersecting"in IntersectionObserverEntry.prototype}},{key:"isSlowConnection",value:function(){return"connection"in navigator&&"effectiveType"in navigator.connection&&("2g"===navigator.connection.effectiveType||"slow-2g"===navigator.connection.effectiveType)}}]),RocketBrowserCompatibilityChecker}();
</script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" id="rocket-preload-links-js-extra">
/* <![CDATA[ */
var RocketPreloadLinksConfig = {"excludeUris":"\/(.+\/)?feed\/?.+\/?|\/(?:.+\/)?embed\/|\/(index\\.php\/)?wp\\-json(\/.*|$)|\/wp-admin\/|\/logout\/|\/pudra\/","usesTrailingSlash":"1","imageExt":"jpg|jpeg|gif|png|tiff|bmp|webp|avif","fileExt":"jpg|jpeg|gif|png|tiff|bmp|webp|avif|php|pdf|html|htm","siteUrl":".","onHoverDelay":"100","rateThrottle":"3"};
/* ]]> */
</script>
<script  data-rocket-type="text/javascript" id="rocket-preload-links-js-after">
(function() {
"use strict";var r="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},e=function(){function i(e,t){for(var n=0;n<t.length;n++){var i=t[n];i.enumerable=i.enumerable||!1,i.configurable=!0,"value"in i&&(i.writable=!0),Object.defineProperty(e,i.key,i)}}return function(e,t,n){return t&&i(e.prototype,t),n&&i(e,n),e}}();function i(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}var t=function(){function n(e,t){i(this,n),this.browser=e,this.config=t,this.options=this.browser.options,this.prefetched=new Set,this.eventTime=null,this.threshold=1111,this.numOnHover=0}return e(n,[{key:"init",value:function(){!this.browser.supportsLinkPrefetch()||this.browser.isDataSaverModeOn()||this.browser.isSlowConnection()||(this.regex={excludeUris:RegExp(this.config.excludeUris,"i"),images:RegExp(".("+this.config.imageExt+")$","i"),fileExt:RegExp(".("+this.config.fileExt+")$","i")},this._initListeners(this))}},{key:"_initListeners",value:function(e){-1<this.config.onHoverDelay&&document.addEventListener("mouseover",e.listener.bind(e),e.listenerOptions),document.addEventListener("mousedown",e.listener.bind(e),e.listenerOptions),document.addEventListener("touchstart",e.listener.bind(e),e.listenerOptions)}},{key:"listener",value:function(e){var t=e.target.closest("a"),n=this._prepareUrl(t);if(null!==n)switch(e.type){case"mousedown":case"touchstart":this._addPrefetchLink(n);break;case"mouseover":this._earlyPrefetch(t,n,"mouseout")}}},{key:"_earlyPrefetch",value:function(t,e,n){var i=this,r=setTimeout(function(){if(r=null,0===i.numOnHover)setTimeout(function(){return i.numOnHover=0},1e3);else if(i.numOnHover>i.config.rateThrottle)return;i.numOnHover++,i._addPrefetchLink(e)},this.config.onHoverDelay);t.addEventListener(n,function e(){t.removeEventListener(n,e,{passive:!0}),null!==r&&(clearTimeout(r),r=null)},{passive:!0})}},{key:"_addPrefetchLink",value:function(i){return this.prefetched.add(i.href),new Promise(function(e,t){var n=document.createElement("link");n.rel="prefetch",n.href=i.href,n.onload=e,n.onerror=t,document.head.appendChild(n)}).catch(function(){})}},{key:"_prepareUrl",value:function(e){if(null===e||"object"!==(void 0===e?"undefined":r(e))||!1 in e||-1===["http:","https:"].indexOf(e.protocol))return null;var t=e.href.substring(0,this.config.siteUrl.length),n=this._getPathname(e.href,t),i={original:e.href,protocol:e.protocol,origin:t,pathname:n,href:t+n};return this._isLinkOk(i)?i:null}},{key:"_getPathname",value:function(e,t){var n=t?e.substring(this.config.siteUrl.length):e;return n.startsWith("/")||(n="/"+n),this._shouldAddTrailingSlash(n)?n+"/":n}},{key:"_shouldAddTrailingSlash",value:function(e){return this.config.usesTrailingSlash&&!e.endsWith("/")&&!this.regex.fileExt.test(e)}},{key:"_isLinkOk",value:function(e){return null!==e&&"object"===(void 0===e?"undefined":r(e))&&(!this.prefetched.has(e.href)&&e.origin===this.config.siteUrl&&-1===e.href.indexOf("?")&&-1===e.href.indexOf("#")&&!this.regex.excludeUris.test(e.href)&&!this.regex.images.test(e.href))}}],[{key:"run",value:function(){"undefined"!=typeof RocketPreloadLinksConfig&&new n(new RocketBrowserCompatibilityChecker({capture:!0,passive:!0}),RocketPreloadLinksConfig).init()}}]),n}();t.run();
}());
</script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/slick.min.js?ver=5.8" id="slick-min-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/jquery.magnific-popup.min.js?ver=5.8" id="jquery-magnific-popup-min-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/iscroll.js?ver=1620657753" id="iscroll-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/fancySelect.js?ver=1620657753" id="fancySelect-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/misc.js?ver=1620657753" id="industrial-misc-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/dir.hover.js?ver=1620657753" id="industrial-dir-hover-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/sliders.js?ver=1620657753" id="industrial-sliders-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/bt_parallax.js?ver=1620657753" id="industrial-bt-parallax-js" defer></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" id="cookie-notice-front-js-extra">
/* <![CDATA[ */
var cnArgs = {"ajaxUrl":".\/wp-admin\/admin-ajax.php","nonce":"870ef1de7b","hideEffect":"fade","position":"bottom","onScroll":"1","onScrollOffset":"100","onClick":"0","cookieName":"cookie_notice_accepted","cookieTime":"604800","cookieTimeRejected":"604800","cookiePath":"\/","cookieDomain":"","redirection":"0","cache":"1","refuse":"0","revokeCookies":"0","revokeCookiesOpt":"automatic","secure":"1"};
/* ]]> */
</script>
<script  async data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/cookie-notice/includes/../js/front.min.js?ver=2.1.0" id="cookie-notice-front-js"></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" src="./../../../../wp-includes/js/wp-embed.min.js?ver=5.8" id="wp-embed-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/moment.js?ver=1620657753" id="bt_moment-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/moment-timezone-with-data.js?ver=1620657753" id="bt_moment_timezone-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/industrial/imagesloaded.pkgd.min.js?ver=5.8" id="boldthemes_imagesloaded-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/industrial/packery.pkgd.min.js?ver=5.8" id="boldthemes_packery-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/bt_grid_tweak.js?ver=1620658021" id="boldthemes_grid_tweak-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/bt_grid.js?ver=1620658021" id="boldthemes_grid-js" defer></script>

<div id="cookie-notice" role="banner" class="cookie-notice-hidden cookie-revoke-hidden cn-position-bottom" aria-label="Cookie Notice" style="background-color: rgba(0,0,0,1);">
<div class="cookie-notice-container" style="color: #fff;">
<span id="cn-notice-text" class="cn-text-container">We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.</span><span id="cn-notice-buttons" class="cn-buttons-container"><a href="#" id="cn-accept-cookie" data-cookie-set="accept" class="cn-set-cookie cn-button bootstrap" aria-label="I AGREE, thank you.">I AGREE, thank you.</a><a href="./../../../../services/privacy-policy/index.html" target="_blank" id="cn-more-info" class="cn-more-info cn-button bootstrap" aria-label="Privacy policy">Privacy policy</a></span><a href="javascript:void(0);" id="cn-close-notice" data-cookie-set="accept" class="cn-close-icon" aria-label="I AGREE, thank you."></a>
</div>
</div>
 <script  data-rocket-type="text/javascript">window.addEventListener('DOMContentLoaded', function() {
        jQuery(document).ready(function ($) {
            //$( document ).ajaxStart(function() {
            //});

			
            for (var i = 0; i < document.forms.length; ++i) {
                var form = document.forms[i];
				if ($(form).attr("method") != "get") { $(form).append('<input type="hidden" name="kNEuIGs" value="ToGFEeP2A" />'); }
if ($(form).attr("method") != "get") { $(form).append('<input type="hidden" name="-rgtSF" value="PeoHbQdFwGR2kU" />'); }
            }

			
            $(document).on('submit', 'form', function () {
				if ($(this).attr("method") != "get") { $(this).append('<input type="hidden" name="kNEuIGs" value="ToGFEeP2A" />'); }
if ($(this).attr("method") != "get") { $(this).append('<input type="hidden" name="-rgtSF" value="PeoHbQdFwGR2kU" />'); }
                return true;
            });

			
            jQuery.ajaxSetup({
                beforeSend: function (e, data) {

                    //console.log(Object.getOwnPropertyNames(data).sort());
                    //console.log(data.type);

                    if (data.type !== 'POST') return;

                    if (typeof data.data === 'object' && data.data !== null) {
						data.data.append("kNEuIGs", "ToGFEeP2A");
data.data.append("-rgtSF", "PeoHbQdFwGR2kU");
                    }
                    else {
                        data.data =  data.data + '&kNEuIGs=ToGFEeP2A&-rgtSF=PeoHbQdFwGR2kU';
                    }
                }
            });

        });
	});</script>
<script src="./../../../../live_search.js"></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript">window.lazyLoadOptions={elements_selector:"img[data-lazy-src],.rocket-lazyload",data_src:"lazy-src",data_srcset:"lazy-srcset",data_sizes:"lazy-sizes",class_loading:"lazyloading",class_loaded:"lazyloaded",threshold:300,callback_loaded:function(element){if(element.tagName==="IFRAME"&&element.dataset.rocketLazyload=="fitvidscompatible"){if(element.classList.contains("lazyloaded")){if(typeof window.jQuery!="undefined"){if(jQuery.fn.fitVids){jQuery(element).parent().fitVids()}}}}}};window.addEventListener('LazyLoad::Initialized',function(e){var lazyLoadInstance=e.detail.instance;if(window.MutationObserver){var observer=new MutationObserver(function(mutations){var image_count=0;var iframe_count=0;var rocketlazy_count=0;mutations.forEach(function(mutation){for(i=0;i<mutation.addedNodes.length;i++){if(typeof mutation.addedNodes[i].getElementsByTagName!=='function'){continue}
if(typeof mutation.addedNodes[i].getElementsByClassName!=='function'){continue}
images=mutation.addedNodes[i].getElementsByTagName('img');is_image=mutation.addedNodes[i].tagName=="IMG";iframes=mutation.addedNodes[i].getElementsByTagName('iframe');is_iframe=mutation.addedNodes[i].tagName=="IFRAME";rocket_lazy=mutation.addedNodes[i].getElementsByClassName('rocket-lazyload');image_count+=images.length;iframe_count+=iframes.length;rocketlazy_count+=rocket_lazy.length;if(is_image){image_count+=1}
if(is_iframe){iframe_count+=1}}});if(image_count>0||iframe_count>0||rocketlazy_count>0){lazyLoadInstance.update()}});var b=document.getElementsByTagName("body")[0];var config={childList:!0,subtree:!0};observer.observe(b,config)}},!1)</script><script data-no-minify="1" async src="./../../../../wp-content/plugins/wp-rocket/assets/js/lazyload/16.1/lazyload.min.js" type="06cd7e663a0e46d4271fe72d-text/javascript"></script><script src="./../../../../cdn-cgi/scripts/7d0fa10a/cloudflare-static/rocket-loader.min.js" data-cf-settings="06cd7e663a0e46d4271fe72d-|49" defer></script><script type="text/javascript">(function(){window['__CF$cv$params']={r:'67b14aa0bd2192f8',m:'43df34172ca0f4f68ebbecbcf9a5a00029aba502-1628347556-1800-AVTlhDW4t9yA80xF5UdjoXKJiq7B7xNjRkAuPvixBxFixLosCDHCFG2h63XgOhBwRiCIDj2P9TKIHYBnV4kRgrcIoT5BrroyHzIFxwvjgkVmd115AGEcIIJPkP66qAQCQm/6tYO8Bkqd31TIv3OlW/z8inBUFtnaZsPjnH1RBzcf',s:[0xc47a4f690a,0xb1c6885590],}})();</script><script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67b14aa0bd2192f8","version":"2021.7.0","r":1,"token":"e3b748a178054eff95051ca851daefa1","si":10}'></script>
</body>
</html>